Skip to main content
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2022 Nov 15;16:1032607. doi: 10.3389/fnins.2022.1032607

The regulatory role of endoplasmic reticulum chaperone proteins in neurodevelopment

Hongji Sun 1, Mengxue Wu 1, Minxin Wang 1, Xiaomin Zhang 1,*, Jia Zhu 2,*
PMCID: PMC9705995  PMID: 36458041

Abstract

The endoplasmic reticulum (ER) is the largest tubular reticular organelle spanning the cell. As the main site of protein synthesis, Ca2+ homeostasis maintenance and lipid metabolism, the ER plays a variety of essential roles in eukaryotic cells, with ER molecular chaperones participate in all these processes. In recent years, it has been reported that the abnormal expression of ER chaperones often leads to a variety of neurodevelopmental disorders (NDDs), including abnormal neuronal migration, neuronal morphogenesis, and synaptic function. Neuronal development is a complex and precisely regulated process. Currently, the mechanism by which neural development is regulated at the ER level remains under investigation. Therefore, in this work, we reviewed the recent advances in the roles of ER chaperones in neural development and developmental disorders caused by the deficiency of these molecular chaperones.

Keywords: neurodevelopment, endoplasmic reticulum, molecular chaperone, neuronal migration, neuronal morphogenesis, synaptic function

Introduction

Neurodevelopment is a highly complex and precisely regulated process (Bagni and Zukin, 2019). The establishment of the human embryonic central nervous system begins on the 22nd day after fertilization when the neural tube begins to form (Devakumar et al., 2018). As development progresses, the anterior portion of the neural tube expands to form “brain vesicles”, and the brain develops from five small vesicle walls filled with fluid (Jiang and Xu, 2019). The initial vesicle wall has only two layers: the compartment layer and the marginal layer (Bostan et al., 2018; Moon and Xiong, 2022). Neural precursor cells (NPCs) are located in the inner layer of vesicles, and cells in the ventricular layer proliferate. Some of the newly generated cells remain in the ventricular layer where they to continue to divide and differentiate. Finally, these cells proliferate and form different brain regional structures, such as the cerebral cortex, thalamus, and hippocampus (Trujillo et al., 2005; Turrero García and Harwell, 2017). Another group of daughter cells located furthest from the ventricle side begin to migrate outward. After these cells reach various regions of the brain and occupy specific locations, they lose their ability to divide, undergo cell differentiation, and finally form the brain (Crelin, 1974; Li and Pleasure, 2014; Belmonte-Mateos and Pujades, 2022).

At the cellular level, NPCs proliferate and differentiate into immature neurons (Riquelme et al., 2008). Then, immature neurons undergo a series of morphological changes, including neuronal axon and dendrite development (Omotade et al., 2018; Prigge and Kay, 2018), axonal myelination, and dendritic spine formation (Nimchinsky et al., 2002), and gradually become mature neurons. Neurons are interconnected by synapses formed by both axonal endings and dendritic spines, forming complex neural networks (Omotade et al., 2018; Kadoyama et al., 2019). Abnormalities in any of these processes may impair neural development, resulting in brain dysfunction and subsequent leading to brain diseases (Guerrini and Dobyns, 2014).

The endoplasmic reticulum (ER) is the largest tubular reticular organelle in eukaryotic cells (Rapoport, 2007; Pobre et al., 2019) and plays several essential roles, including Ca2+ storage and release, lipid synthesis, intracellular signaling, and protein synthesis (Phillips and Voeltz, 2016; Schwarz and Blower, 2016). ER molecular chaperones are a class of proteins ubiquitous in living organisms and are widely found in prokaryotes and eukaryotes (Doyle et al., 2013; Bose and Chakrabarti, 2017). These molecular chaperones are mainly responsible for assisting in correct protein folding, assembly, trans-location, degradation of misfolded proteins and inhibition of protein aggregation to maintain normal protein homeostasis (Carver et al., 2018; Freilich et al., 2018; Takeuchi, 2018; Ma et al., 2020).

Studies have found that abnormal expression of molecular chaperones often leads to abnormal neurodevelopment and even causes a variety of different neurodevelopmental diseases (Fatemi et al., 2005; Lammert et al., 2017). ER chaperones involved in neural development are mainly divided into the following categories: heat shock family proteins including heat shock protein 70 (HSP70) and heat shock protein 90 (HSP90) (Miller and Fort, 2018), glycan-binding lectin chaperones including calnexin (CNX) and calreticulin (CRT) (Ni and Lee, 2007), protein disulfide isomerase (PDI) (Turano et al., 2002), sigma-1 receptor (Sig-1R) (Su et al., 2010; Zhemkov et al., 2021; Dalwadi et al., 2022) and prefoldin (PFDN) (Siegert et al., 2000).

HSP70 and HSP90, members of the heat shock protein family, are highly conserved and ubiquitous molecular chaperones (Tsuboyama et al., 2018). The reversible interaction between HSP70 and peptides plays an important role in protein folding, transport, degradation of misfolded peptides and maintenance of cellular homeostasis (Fernández-Fernández and Valpuesta, 2018). HSP90 and its co-chaperones coordinate key physiological processes, such as cell survival, cell cycle control, hormone signaling, and apoptosis (Hoter et al., 2018). Binding immunoglobulin protein (Bip) and glucose-regulated protein 94 (GRP94) are the main HSP70 and HSP90 proteins in the ER. Bip cannot function alone, and the binding and separation between Bip and nascent proteins require the participation of other auxiliary proteins, such as the cochaperone SIL1, the main function of which is to serve as a nucleotide exchange factor (NEF) to assist Bip protein in binding nascent peptide chains and mediating their folding and assembly (Otero et al., 2010). However, GRP94 expression in the ER is mostly related to tumor cancer and other related diseases (Gewirth, 2016). CRT and CNX bind Ca2+ and act as molecular chaperones in the transition of proteins from the ER to the extracellular membrane and regulate Ca2+ balance in the ER (Tjoelker et al., 1994). In addition to assisting protein folding consistent with the Sig-1R and PFDN protein, PDI is also involved in the formation and isomerization of disulfide bonds to prevent intermolecular aggregation (Wilkinson and Gilbert, 2004).

In addition, in the ER, chaperones not only exert their respective functions individually but also interact with each other to maintain ER homeostasis and protein homeostasis. For example, glycan-binding lectin chaperones form the glycosylation-deglucosylation cycle. As a reticulin, CRT is involved in a quality control system for newly synthesized proteins and glycoproteins that relies on multiple additional chaperons, including CNX and protein disulfide isomerase family A member 3 (PDIA3) (Fucikova et al., 2021). This system is often referred to as the CNX/CRT cycle. The CNX/CRT cycle specifically recognizes glycoproteins linked by N2 glycosidic bonds and is an important monitoring mechanism for protein folding and assembly in eukaryotic cells as well as regulating Ca2+ homeostasis and Ca2+ signaling processes (Insert a) in the ER (Helenius and Aebi, 2001). As a highly conserved molecular chaperone, Bip assists in a wide range of folding processes through its two domains: the nucleotide binding domain (NBD) and the substrate binding domain (SBD) (Mayer and Gierasch, 2019). When adenosine diphosphate (ADP) binds the NBD, the SBD conformation changes, and the substrate binding affinity of Bip increases. The SBD lid closes on the bound substrate, limiting the conformational freedom of the substrate and protecting the bound substrate from premature folding or aggregation (Hendershot et al., 1996). The NEF of Bip can break the hydrogen bond contact and detach the bound ADP molecule (Tyson and Stirling, 2000) so that NBD can bind to the new adenosine triphosphate (ATP) molecule, and the substrate binding affinity is reduced. SBD docks on the NBD and opens the lid to release the bound polypeptide substrate (Insert b). At present, SIL1 and glucose-regulated protein (GRP170) are the two co-chaperones that can bind Bip to promote NEF activity (Yan et al., 2011). Bip is also a regulator of Ca2+ homeostasis in the ER, maintaining Ca2+ balance in the ER (Lièvremont et al., 1997). In addition, when unfolded/misfolded proteins in the ER exceed the capacity of the protein folding mechanism, Bip can initiate the unfolded protein response (UPR), assist in ER-associated degradation (ERAD), reduce the unfolded/misfolded protein load, and induce autophagy (Wang J. et al., 2017).

Recent studies have shown that many ER chaperone proteins participate in neural development. Therefore, in this work, we review the regulatory roles of ER chaperones in various stages of central nervous system development as well as recent research progress on related neurodevelopmental diseases.

The role of binding immunoglobulin protein in neurodevelopment

Heat shock proteins are a large family of evolutionarily conserved molecular chaperones that play key roles in cell survival and development, and their expression is induced by different factors, including heat shock, nutrient deficiency, hypoxia, and intoxication (Tsuboyama et al., 2018). HSP70 family plays an essential role in protein folding, transport, degradation of misfolded polypeptides, and maintenance of cellular homeostasis (Fernández-Fernández and Valpuesta, 2018). Among them, Bip [also known as glucose-regulated protein 78 (GRP78) or heat shock protein A5 (HSPA5)] with a molecular weight of 78 kDa, mainly exists in the ER and is responsible for binding the nascent peptide chain and mediating its folding and assembly (Wang et al., 2009). Bip cannot perform its functions alone, but other auxiliary proteins are required for its binding and separation from nascent proteins (Otero et al., 2010). The effects of Bip on neurodevelopmental processes are mainly reflected in embryonic development, cortical neuron migration, and coordination of developmental processes in conjunction with some ER cochaperone proteins.

Binding immunoglobulin protein regulates the migration and localization of developing cortical neurons

Mutant mice with Bip deficiency die during the embryonic period (Luo et al., 2006; Jin et al., 2017), and the main cause of death is abnormal expression of the pulmonary surfactant protein surfactant protein-A (SP-A) and prominently surfactant protein-C (ProSP-C), which subsequently triggers respiratory insufficiency in neonatal or newborn mice and leads to death. In addition to respiratory failure, Bip mutant mice exhibit abnormal neuronal migration and dysplasia. Normal cortical neurogenesis in the ventricular zone (VZ), and newborn neurons migrate to different layers of the cerebral cortex through radial migration (Nadarajah and Parnavelas, 2002; Marín et al., 2010). Neurons generated earlier migrate to the deep cortex, whereas neurons generated later migration to shallow layers (Ghashghaei et al., 2007; Kwan et al., 2012). The subplate (SP), cortical plate (CP), and marginal zone (MZ) are formed in an inside-out migration pattern during development (Caviness, 1982). However, newborn neurons in Bip mutant mice are the first to migrate to the MZ and remain there, whereas later-born neurons fail to migrate to the upper layers. The mutant brain exhibits an outside-in pattern during neocortical layer formation. This phenotype is observed because loss of Bip affects the expression of reelin, a protein that plays an essential role in neuronal migration. In wild-type mice, reelin-secreting Cajal-Retzius (CR) cells are located in the superficial layer of the cortex. In contrast, CR cells in mutant Bip mice are scattered around the upper layer of the neocortical primordium, and CR cells in Bip mutants do not secrete reelin. Therefore, Bip mutant mice exhibit a phenotype similar to that of reelin knockout mice (Mimura et al., 2008).

Binding immunoglobulin protein regulates motor neuron development

Heterozygous mutant Bip mice exhibit no significant difference in lifespan compared with wild-type mice, but mutant Bip mice develop renal tubular-interstitial lesions as they age (Kimura et al., 2008). Some mutant Bip mice develop paralysis and tremors after 12 months. These mice exhibit motor nerve injury symptoms, such as loss of righting reflex, and suffer from paralysis (Jin et al., 2014). In addition, studies have shown that Bip deletion is associated with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons (Beghi et al., 2011; Filareti et al., 2017). In recent years, impaired protein homeostasis has been found to be a key factor in the pathogenesis of ALS (Zhao et al., 2008; Ruegsegger and Saxena, 2016), and Bip plays an important role in this process. Studies have found that Bip-deficient mice show more severe neurological decline and spinal motor neuron loss symptoms than normal mice. Gómez-Almería et al. created mutant superoxide dismutase 1 (mSOD1) and Bip double mutant (mSOD1/Bip+/-) mice to study the role of Bip in a mouse model of the neurodegenerative disease ALS (Gómez-Almería et al., 2021). They found that knockout of Bip show more intense neurological decline than mSOD1 single knockout mice. Then, to determine the relationship between the Bip protein and the pathogenesis of ALS, they also discussed the potential relationship between the Bip protein and the type-1 cannabinoid (CB1) receptor that mediates neuroprotection. CB1 receptor is mainly located in neurons of the central nervous system (Chiarlone et al., 2014). Numerous studies have reported that CB1 receptor-mediated neuroprotection is related to ALS (Abood et al., 2001; Rossi et al., 2010). They found that in mSOD1 mice with partial Bip gene deletion, the level of the CB1 receptor was significantly decreased, which indirectly indicated that Bip may play a neuroprotective role in ALS (Gómez-Almería et al., 2021). Similarly, Apolloni et al. found that increasing Bip and Hsp70 protein levels in the spinal cord and cortex of ALS model mice could rescue the loss of motor neuron dendritic spines (Apolloni et al., 2019). These studies suggest that Bip plays vital roles in motor neuron development.

Binding immunoglobulin protein regulates the plasticity of the central nervous system

Studies have shown that the interaction between Bip and N-methyl-D-aspartate (NMDA) receptors may affect synaptic transmission. NMDA receptors play essential roles in brain development, plasticity, and pathology. Functional NMDA receptors are tetramers mainly composed of two GluN1 subunits and two GluN2 regulatory subunits (Cull-Candy et al., 2001; Yashiro and Philpot, 2008). The number and composition of GluN2A and GluN2B containing NMDA receptors at synapses are dynamically regulated during development and neuronal activation, which is thought to control synaptic plasticity (Nase et al., 1999; Lopez de Armentia and Sah, 2003; Liu et al., 2004). Using immunoprecipitation, the authors examined the distribution of Bip in neurons and found that Bip is strongly expressed in both cortical and hippocampal neuronal cell bodies and neurites. Furthermore, Bip co-localizes with GluN2A in cultured cortical neuron dendrites, and preventing the binding of Bip to GluN2A reduces synaptic transmission and impairs memory formation (Zhang et al., 2015).

Binding immunoglobulin protein and SIL1 jointly regulate neural development

SIL1 is a 54-kDa ER protein composed of 461 amino acids and is a NEF for Bip (Wang J. et al., 2017). As an auxiliary protein of Bip, the synergistic effect of SIL1 and Bip has consistently been a research hotspot. The central nervous system of mice with SIL1 deficiency exhibits developmental defects, including abnormal neuronal morphological development, cortical neuron migration, and localization (Inaguma et al., 2014).

SIL1-binding immunoglobulin protein coordinately regulates neuronal migration

SIL1 plays a role in neuronal migration in the neocortex. Inaguma et al. constructed a SIL1 knockout plasmid, transfected it into the neural progenitor cells of the VZ of the embryonic mouse brain through in utero electroporation (Tabata and Nakajima, 2001; Nishimura et al., 2012) and observed the localization of the transfected cells at the post-natal day 0 (P0). In the control group, neurons normally migrated to the superficial layers (layers II-IV) of the CP, whereas the SIL1-deficient neurons remained in the middle or lower layers of the CP. Then, the authors performed immunostaining to assess the differentiation status of the abnormally localized cells and found that the abnormally localized cells remained in the immature neuronal state (NPCs or basal progenitor cells) (Inaguma et al., 2014).

Considering that SIL1 acts as a chaperone for Bip and regulates its function, Bip may also be involved in neuronal migration. Therefore, Inaguma et al. also examined the role of Bip in neuronal migration during cortical formation and compared it with SIL1. They found that a large fraction of Bip-deficient (through RNA interference) neural progenitor cells, which remain in the lower part of CP, intermediate zone (IZ), and subventricular zone (SVZ)/VZ at P0, exhibit a phenotype similar to that of SIL1-deficient cells. Bip-deficient neurons showed delayed migration at embryonic day 17 (E17) but localized in normal positions at post-natal day 7 (P7). However, after inhibiting the SIL1-Bip interaction, neuronal migration was significantly inhibited. In conclusion, the coordination function of SIL1 and Bip plays a key role in neuronal migration (Inaguma et al., 2014).

SIL1 and binding immunoglobulin protein jointly regulate reelin protein and affect development

In addition to regulating neuronal migration during cortical development, Reelin is currently believed to be involved in neuronal dendrite development and changes in brain plasticity (Niu et al., 2004; Jossin and Goffinet, 2007). The distribution of cortical neurons in heterozygous reeler (Reelin knockout) mice did not appear disordered, but their dendritic development was affected. Dendritic spine density decreased on the dendrites of pyramidal neurons in the CA1 region of the mouse hippocampus at 21 and 32 days after birth, whereas more mature neurons showed a lower density of dendritic spines accompanied by decreased expression levels of post-synaptic density protein 95 (PSD95) and NMDA receptors (Niu et al., 2008). These findings indicate that Reelin promotes dendritic development and the generation and maintenance of dendritic spines during post-natal development. The loss of Bip is one of the reasons for the down-regulation of Reelin protein, indicating that Bip may affect the development of dendrites and dendritic spines by affecting Reelin protein expression. Loss of SIL1, Bip, or Reelin function leads to similar abnormal phenotypes of neuronal migration (Leemhuis and Bock, 2011; Stranahan et al., 2013), and the loss of function of the ER molecular chaperone Bip inhibits normal Reelin expression. Thus, the relationship among these three proteins during neural development and whether the role played by Reelin protein in development is co-regulated by the coordination of Bip and SIL1 represent questions that deserve to be explored.

The role of calnexin during neurodevelopment

Calnexin is a 90-kDa ER integral protein with a long amino-terminal domain (460 amino acids) located in the lumen of the ER, a hydrophobic trans-membrane domain and a short acidic cytoplasmic domain (91 amino acids). CNX binds to Ca2+ and acts as a chaperone in the transition of proteins from the ER to the outer membrane (Tjoelker et al., 1994). CNX and CRT constitute the CNX/CRT cycle and are responsible for the folding and quality control of newly synthesized proteins (Li et al., 2011).

Many researchers have confirmed the role of CNX as a molecular chaperone in neurodevelopment. The CANX gene (coding CNX) is activated in neuronal tissue early in embryonic development (Coe et al., 2008). Immunohistochemical staining of mouse brain tissue sections showed that CNX exists in hippocampal neurons and is expressed at high levels in soma, dendrites, and synapses (Itakura et al., 2013). Additional studies have shown that in mice, CNX deficiency leads to a phenotype of peripheral axonal demyelination and reduced peripheral nerve conduction velocity, demonstrating that CNX may play an essential role in neuron growth and development (Jung et al., 2018).

Calnexin regulates dendrite and synapse development

Denzel et al. found that approximately 50% of CNX knockout mice died within 48 h after birth, most of the remaining mice died within 4 weeks, and only a few mice survived to 3 months (Denzel et al., 2002). CNX gene knockout (cnx–/–) mice exhibited significant movement impairment, including unsteady gait, inactive walking, and obvious trunk ataxia. The authors then examined the sciatic nerve in the gene-deficient mice through electron microscopy and found that most of the mice exhibited a reduced number of medullary nerve fibers and a reduced sciatic nerve diameter (Denzel et al., 2002). However, the cause of the short-lived death of cnx–/– mice has not yet been discovered but might be related to the coordinating role of CNX proteins in development. This hypothesis deserves further exploration.

Recent studies assessing the localization of CNX and NMDA receptors on neurons based on specific immunostaining and biotin chemical reagent labeling revealed that a considerable portion of CNX was localized on the cell surface of cultured neurons, and this localization was regulated by NMDA receptors (Itakura et al., 2013). These results suggest that CNX may play an essential role in NMDA receptor-mediated neuronal function. Other studies demonstrated that α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors interact with CNX and Bip in neuronal cell bodies and hippocampal pyramidal neuron dendrites (Rubio and Wenthold, 1999; Gerrow and Triller, 2010). In addition, the AMPA receptor is a tetramer composed of four subunits, GluA1, GluA2, GluA3, and GluA4. This receptor is expressed in both neurons and glial cells (Pick and Ziff, 2018). It is well known that NMDA receptors and AMPA receptors play essential roles in central nervous system development. NMDA receptors are involved in experience-dependent synapse and dendritic development (Nadarajah and Parnavelas, 2002; Luo et al., 2006), whereas AMPA receptor expression directly affects neuronal dendritic complexity, synaptic maturation, and neural network formation (Buffington et al., 2014). Defects in AMPA receptor expression are the underlying causes of developmental diseases, degenerative diseases, and cognitive dysfunction (Kessels and Malinow, 2009; Henley and Wilkinson, 2016; Guo and Ma, 2021). However, the specific effects of CNX loss on NMDA receptor or AMPA receptor membrane expression or function remain to be investigated. Moreover, studies have shown that CNX can be attached to membranes through NMDA receptor-mediated pathways (Itakura et al., 2013). Therefore, CNX may regulate central development by participating in receptor function at the cell membrane. In addition, CNX regulates calcium levels in the ER (Roderick et al., 2000), which subsequently regulates receptor transport to influence synaptic strength (Turrigiano, 2008). Therefore, CNX may directly affect synaptic strength and synaptic development through this mechanism. However, the direct correlation between CNX and synaptic development and function needs to be expanded.

Calnexin cooperates with the cytoskeleton-associated protein to regulate neural plasticity

Activity-regulated cytoskeleton-associated (Arc) protein is a master regulator of long-term synaptic plasticity and memory formation (Bramham et al., 2010; Korb and Finkbeiner, 2011; Shepherd and Bear, 2011; Nikolaienko et al., 2017). Arc proteins control synaptic strength by promoting AMPA receptor endocytosis (DaSilva et al., 2016) and activity-dependent long-term changes in synaptic strength (Ehlers, 2000; Newpher and Ehlers, 2008). Arc overexpression decreased the density of GluA1 subunits of AMPA receptors on the cell surface and AMPA receptor-mediated miniature excitatory post-synaptic currents (mEPSCs). Arc mutations that prevent clathrin-adaptor protein 2 (AP-2) interaction reduce Arc-mediated endocytosis of GluA1 and abrogate AMPA receptor-mediated mEPSCs reduction (DaSilva et al., 2016). Endocytosis is the process by which cells internalize substances through the plasma membrane. Endocytosis plays an important role in different stages of the development of the nervous system, such as the formation of continuous synaptic transmission (Sudhof, 2004), the entry of drugs into the central nervous system (Smith et al., 2008), and the internalization of receptor-ligand complexes to nerve endings for intracellular signaling (Gloor et al., 2001). CNX is also involved in clathrin-mediated endocytosis of neurons (Li et al., 2011). Kraus et al. performed an electron microscopy analysis of the cerebellum of 7-day-old wild-type and CNX-null mice to assess whether CNX is involved in neuronal endocytosis. The results showed that the number of synaptic vesicles was significantly increased in the cerebellum of CNX-deficient mice compared with wild-type mice, demonstrating that CNX deficiency leads to increased endocytic activity in the mouse neuronal system (Kraus et al., 2010). Recent studies have found a direct interaction between Arc and CNX in neurons, and the interaction between recombinantly expressed glutathione S-transferase (GST)-tagged Arc and endogenous CNX has also been found in HEK293, SH-SY5Y neuroblastoma, and PC12 cells (Myrum et al., 2017). Given that both Arc and CNX mediate clathrin-dependent endocytosis and that both are expressed in excitatory synapses, it is possible that Arc and CNX cooperate in regulating endocytosis. Therefore, whether CNX is involved in the synaptic effect is also a mechanism that needs further exploration.

Calreticulin regulates neurodevelopment

Calreticulin is a multifunctional protein with a molecular weight of 46 kDa. CRT is expressed in almost all eukaryotic cells and is preferentially located in the ER. Depending on the sublocalization of CRT in cells, CRT has different physiological functions, including chaperone function and lectin binding. CRT was initially considered to be a high-affinity calcium-binding protein (Rauch et al., 2000), and early studies focused on its role as a calcium storage molecule in the ER (Michalak et al., 1992), including regulating calcium channel activation and maintaining intracellular calcium homeostasis (Chen et al., 2015). Later, CRT was considered a multifunctional protein that interacts with other proteins and participates in various processes (Michalak et al., 1999). In recent years, the focus of CRT research has been refocused to its role as an ER chaperone that aids in glycoprotein folding (Pacheco et al., 2020). The role of CRT in neurodevelopment mainly involves regulating embryonic development, neural differentiation, and axonal growth in the peripheral nervous system.

Calreticulin regulates embryonic development of the central nervous system

To study the role of CRT during development in vivo, Rauch et al. generated CRT-deficient mice by targeted inactivation of the CRT gene. The results demonstrated that CRT heterozygous mice were viable and fertile, whereas crt–/– mice were embryonic lethal and exhibited multiple disease phenotypes, including cardiomyopathy, anencephaly, and omphalocele (Rauch et al., 2000). In addition, CRT is also important for cranial neural tube closure and is highly expressed in the developing brain during neurogenesis (Mesaeli et al., 1999). Neural tube formation is a complex process that requires the interaction of neuroepithelial cells and the underlying mesenchyme (Lynch et al., 2012; Correll et al., 2019). Disruption of neural tube closure was found in several CRT knockout mice, in which proteins involved in neuronal migration and calcium signaling were inactivated (Solheim et al., 1997; Rauch et al., 2000). These results demonstrate that CRT is important for embryonic brain development, especially the neural tube development. However, it is currently unclear which proteins interact with CRT to regulate embryonic neural development.

Calreticulin regulates neuronal differentiation

Neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), and neurotrophic factor-4/5 (NT-4/5), are key tissue factors that control nervous system development (Chao, 2003). The NGF/tyrosine receptor kinase A (TrkA) signaling pathway is necessary for neural development, and abnormalities in this pathway can lead to abnormal neuronal differentiation. Shih et al. found that in NGF-stimulated PC12 cell differentiation, CRT levels were increased by activation of mitogen-activated protein kinase (MAPK) mediated by extracellular signal-regulated kinase (ERK). CRT deficiency significantly reduced NGF-induced neuronal differentiation. Furthermore, CRT overexpression enhanced neuronal differentiation through simultaneous activation of the ERK-dependent MAPK pathway (Shih et al., 2012). The Ca2+ regulation ability of CRT is also essential for NGF-triggered neuronal differentiation (Pilquil et al., 2020). In addition, studies have shown that CRT is a novel oncogenic N-MYC (MYCN) inhibitor that can down-regulate MYCN promoter activity and protein expression to regulate neuronal differentiation. This study also found that CRT-mediated MYCN inhibition resulted in increased neurite length (Lee et al., 2019).

Calreticulin regulates axonal growth in the peripheral nervous system

Calreticulin localizes to axons of cultured dorsal root ganglion neurons in vitro and peripheral nervous system axons in vivo (Willis et al., 2005; Vuppalanchi et al., 2010), and automatic axonal regeneration occurs after injury to adult peripheral neurons (Bradke et al., 2012). The intrinsic growth capacity of peripheral nervous system axons after injury is greater than that of central nervous system axons. Pacheco et al. constructed in vitro and in vivo neuronal axonal injury models to study the relationship between CRT and axonal regeneration after axonal injury. Intra-axonal CRT levels were elevated after peripheral nerve injury in vivo. Unilateral sciatic nerve crush injury was performed in the mid-thigh of male SD rats, and then sciatic nerve sections were collected and stained 1 h, 6 h, 18 h, and 7 days after the crush injury. Compared with the control sciatic nerve, axonal CRT levels were significantly increased 6 h after injury and reached a maximum at 18 h after injury. The authors then performed axotomy on dorsal root ganglion neurons to study the effect of CRT deletion on the post-operative axonal growth process. The results showed that the shRNA-mediated CRT deletion group exhibited exacerbated post-axotomy contractions. In contrast, axon-targeted expression of unrestricted CRT mRNA reduces contraction and promotes axon regeneration after axotomy in vitro (Pacheco et al., 2020). In conclusion, the overexpression of axon-targeted CRT promotes axon regeneration after axonal injury, indicating that CRT plays an important role in axonal growth.

The role of protein disulfide isomerase in neurodevelopment

Protein disulfide isomerase is a class of multifunctional proteins present in the ER lumen, including endoplasmic reticulum protein 57 (ERp57, also known as PDIA3), endoplasmic reticulum protein 29 (ERp29), protein disulfide isomerase-1 (PDI-1), endoplasmic reticulum protein 72 (ERp72), protein disulfide isomerase A1 (PDIA1), and protein disulfide isomerase p (PDI p) (Turano et al., 2002). As a molecular chaperone, PDI binds to the stretched or partially folded peptide chain through its polypeptide binding site to form an intermediate to prevent incorrect protein folding (Wilkinson and Gilbert, 2004).

Protein disulfide isomerase-1 regulates neuronal migration

Protein disulfide isomerase-1 controls neuronal migration by regulating Wnt secretion. PDI is a family of protein chaperones that reside in the ER and are capable of catalyzing the formation (oxidation), cleavage (reduction), and rearrangement (isomerization) of disulfide bonds (Wilkinson and Gilbert, 2004). The formation of a proper Wnt protein structure requires the formation of disulfide bonds, which are critical for Wnt secretion and signaling (Zhang X. et al., 2012; MacDonald et al., 2014). Wnt proteins play essential roles in neuronal migration and axon-dendritic guidance in vertebrates (Yoshikawa et al., 2003; Bocchi et al., 2017), and they also control neural developmental processes in C. elegans, including neuronal migration, polarity, and axon guidance (Coudreuse et al., 2006; Hilliard and Bargmann, 2006; Pan et al., 2006). Therefore, abnormal Wnt expression or function significantly impairs neural development.

PDI-1 controls the secretion of EGL-20, the Wnt homolog in C. elegans, and therefore affects neuron migration (Torpe et al., 2019). EGL-20/Wnt is expressed and secreted in subcutaneous (epidermal) and muscle cell subsets of C. elegans (Whangbo and Kenyon, 1999). EGL-20 function is critical for the migration of hermaphroditism-specific neuron (HSN) (Desai et al., 1988). Torpe et al. used HSN development as a readout of EGL-20 function to identify molecules that control Wnt maturation and secretion. They hypothesized that PDI is important for EGL-20-directed HSN development. The expression of five PDI-encoding genes (pdi-1, pdi-2, pdi-3, pdi-6, and C14B9.2) in C. elegans was reduced using RNA interference, and the development of HSN was analyzed. This study found a specific requirement for PDI-1 during HSN development with approximately 20% of PDI-1-silenced animals exhibiting a phenotype deficient in HSN migration. Subsequently, to determine whether PDI-1 also controls EGL-20-dependent post-embryonic neuron development, the authors performed post-embryonic neuronal migration assays in PDI-1-deficient animals and found that PDI-1 knockout animals exhibited migration defects (Torpe et al., 2019). PDI inhibitors reduce Wnt3a secretion in human cells. Most mammalian genomes contain 19 Wnts and greater than 20 PDI proteins, which exhibit distinct expression domains and biological functions (Ellgaard and Ruddock, 2005; Galligan and Petersen, 2012; Willert and Nusse, 2012). Mammalian Wnt3a secretion was abolished when a single cysteine residue was replaced by alanine (MacDonald et al., 2014), suggesting that Wnt secretion is influenced by disulfide coordination. These results suggest that PDI can affect neuronal migration by regulating the secretion of Wnt and its homolog EGL-20.

The role of the Wnt signaling pathway in early cortical development is not limited to the migratory localization of neurons. It is also involved in neurogenesis, neuronal differentiation, and axon-dendritic guidance (Freese et al., 2010; Munji et al., 2011). In addition, the atypical Wnt signaling pathway is involved in the assembly of neural circuits (Hinata et al., 2007; Wang et al., 2011), especially dendrite development and synaptogenesis in cultured pyramidal neurons (Salinas and Zou, 2008). Wnt pathway dys-regulation is closely related to human neurological diseases (Castelo-Branco et al., 2003). However, the mechanism by which PDI further affects other developmental processes by affecting the Wnt signaling pathway is unclear and deserves further exploration.

The role of sigma-1 receptor in neurodevelopment

Sigma-1 receptor is a 223-amino acid long trans-membrane ER chaperone with a molecular weight of 25.3 kDa (Hanner et al., 1996; Dalwadi et al., 2022). Most Sig-1R proteins are located in the ER, especially in the mitochondria-associated ER membrane, and are critical for regulating energy balance and calcium homeostasis (Hayashi and Su, 2007). Sig-1R is highly expressed in the central nervous system, especially in the cortex, basal ganglia, spinal cord, and brainstem. It is also vital to maintain the proper functioning of motor neurons (Su et al., 2010). Sig-1R has recently attracted extensive attention as a potential drug target for neurological diseases and cancer (Merlos et al., 2017; Penke et al., 2018).

Recently, Sig-1R was shown to be important in neurodevelopmental research as an ER chaperone and is known to be involved in learning and memory. Within the nervous system, Sig-1R is predominantly localized in the gray matter of neurons and multiple glial cell types (Peviani et al., 2014; Robson et al., 2014). In addition to its role in regulating intercellular signaling (Su et al., 2010), neuroprotection (Ruscher et al., 2011), neural recovery (Ruscher et al., 2012), neuroplasticity (Kourrich et al., 2012), and neurotransmitter release (Zheng, 2009), Sig-1R also regulates various neural developmental processes, such as hippocampal neuronal dendritic morphogenesis, dendritic spine maturation, and neuroplasticity.

Sigma-1 receptor regulates neuronal morphogenesis

Sigma-1 receptor regulates neurite outgrowth (Ishima et al., 2014) as well as primary neuron morphogenesis (Ishima and Hashimoto, 2012). Dendritic spines in hippocampal neurons play important roles in neuroplasticity and memory formation. siRNAs were used to silence the expression of Sig-1R to study their role in the morphogenesis of primary hippocampal neurons in vitro. The results showed impaired dendrite extension and branching after Sig-1R gene silencing. Moreover, Sig-1Rs also have a major impact on the formation and maturation of dendritic spines in later stages (Tsai et al., 2009). In rat hippocampal primary neurons, reducing the expression of Sig-1Rs by siRNA resulted in defects in dendritic spine formation. Tsai et al. observed and analyzed the dendritic spine morphology and maturity of cultured hippocampal neurons. On DIV 16, the control group neurons formed filamentous protrusions on the dendrites. On DIV 22, control neurons formed clusters of short, thick mushroom-like spine heads without filopodia, indicating spine maturation. In contrast, Sig-1R-siRNA-transfected (siSig-1R-tf) neurons formed elongated protrusions with a few spine heads at the tips. The longer the culture time, the more pronounced the abnormal phenotype. This finding suggests that Sig-1Rs are endogenous regulators of hippocampal dendritic spine formation (Tsai et al., 2009).

Sigma-1 receptor regulates synaptic function

Sigma-1 receptor also plays an important role in the development of synaptic function (Ryskamp et al., 2019). Active synapses express specific proteins and receptors for proper function. Studies have shown that Sig-1R knockdown inhibits functional synapse formation. GluA2, GluA3, and PSD-95 staining revealed a strong immune response on dendritic spines in control neurons. However, this response was not observed in filopodia protrusions of siSig-1R-tf neurons, whereas these proteins were still present in dendritic shafts. The axonal terminals of siSig-1R-tf neurons also showed significantly reduced immune responses to synaptophysin. Neurons labeled with FM4-64, a membrane-selective red fluorescent dye, were depolarized with KCl to measure synaptic activity. The results showed that siSig-1R-tf neurons did not form functional synapses. These results suggest that Sig-1Rs have essential effects on synapse formation and synaptic function (Ryskamp et al., 2019).

Earlier, we mentioned that the NMDA receptor is associated with learning and memory. A study found that changes in Sig-1R can cause changes in NMDA receptor expression. Sig-1R was overexpressed by intraperitoneal injection of the Sig-1R activation agonist SKF10,047 in SD rats, and subsequent immunofluorescence staining revealed increased GluN2A, GluN2B, and PSD95 expression (de Montigny et al., 1992; Monnet et al., 1994, 1996). This effect was abolished after the addition of the Sig-1R antagonist BD1063 (Matsumoto et al., 1995; McCracken et al., 1999). In addition, they found increased interactions between Sig-1R and GluN2 subunits as well as increased surface levels of NMDA receptor upon Sig-1R activation, which suggests that Sig-1R regulates the expression of NMDA receptor and related neural function (Pabba et al., 2014).

Sigma-1 receptor regulates mitochondrion-associated endoplasmic reticulum membrane conduction and affects neural development

The membrane of the ER of a cell forms contacts directly with mitochondria, and the contact is referred to as the mitochondrion-associated ER membrane (MAM) (Mori et al., 2013). The MAM is a subdomain of the ER that engages in a direct physical association with mitochondria (Rizzuto et al., 2004; Csordás et al., 2006; Szabadkai et al., 2006). The MAM integrates many signaling pathways and is important for cellular survival because it serves as the “tunnel” for lipid transport and Ca2+ signaling between the ER and mitochondria (Cárdenas et al., 2010). Sig-1Rs are ER chaperones that localize specifically at the MAM and regulate a variety of cellular functions including Ca2+ signaling between ER and mitochondria, neuronal differentiation, ion channel activities, and notably cellular survival (Aydar et al., 2002; Fontanilla et al., 2009; Fukunaga and Moriguchi, 2017). However, exactly how Sig-1R regulates the neuronal differentiation process at the MAM is not fully clarified. Neurons are highly differentiated cells and require great amounts of ATP for the maintenance of cell membrane ionic gradients and neurotransmission (Xavier et al., 2016). Mitochondria, the main intracellular energy transducers, play a key role in neural development by producing ATP and biosynthetic substrates, regulating Ca2+ homeostasis, and initiating apoptosis (Kann and Kovács, 2007). Given the vital role of Sig-1R in the MAM and the importance of energy transport for neural development, exploring the energy transduction mechanism of Sig-1R in the MAM may be key to studying the developmental process.

The function of prefoldin during neurodevelopment

Prefoldin is a heterohexameric protein complex (Glover and Clark, 2015) consisting of two α subunits (PFDN3 and PFDN5) and four β subunits (PFDN1, PFDN2, PFDN4, and PFDN6). PFDN interacts with nascent polypeptide chains and can act as a substitute for Hsp70 in vitro to facilitate protein folding and prevent intermolecular aggregation (Siegert et al., 2000). In recent years, studies have found that PFDN regulates the toxicity of misfolded proteins, including those that lead to neurodegenerative diseases. For example, PFDN can protect neuronal cells from polyglutamine toxicity by preventing aggregate formation or maintaining proteostasis by unfolding misfolded proteins in physiopathological conditions (Tashiro et al., 2013; Tahmaz et al., 2022). PFDN-deficient mice exhibit phenotypic features of defective cytoskeletal function, including ciliary dyskinesia, neuronal loss, and defects in B- and T-cell development and function. As ubiquitous components of the cytoskeleton, actin and tubulin play essential roles in multiple stages of neural development, including dendritic axon growth, neuronal polarization, neuronal migration, and synaptic signal transduction (Cao et al., 2008; Bertling and Hotulainen, 2017), whereas efficient synthesis of actin and tubulin requires the participation of the protein complex formed by PFDN and t-complex protein 1 ring complex (TRiC)/chaperonin-containing t-complex protein 1 (CCT). As an ER chaperone, PFDN promotes the post-translational folding of actin and other cytoskeletal proteins through the t-complex protein 1 (TCP1)-containing loop complex chaperone TRiC (Cao et al., 2008). PFDN and TCP1 play essential roles in metazoan development. In C. elegans, RNA interference screens revealed that knockdown of a single PFDN or TCP1 subunit resulted in morphological abnormalities and distinct penetrating embryonic lethal phenotypes (Delgehyr et al., 2012), suggesting that these proteins are essential in multiple tissue development and early embryonic development (Monzo et al., 2010). In contrast, PFDN1-deficient mice develop defective cytoskeletal function, loss of neural tracts, hydrocephalus, neuromuscular defects, abnormal lymphocyte development and function, and shortened lifespan (Lee et al., 2011). Furthermore, abnormal actin and/or tubulin cytoskeleton assembly and microtubule formation may underlie the Pfdn5nmf5a (encoding PNDF5) disease phenotype, including photoreceptor degeneration (Kwon et al., 2019), central nervous system abnormalities, and male sterility (Lee et al., 2011). Although PFDN5 is expressed in various tissues, defects in PFDN5 homozygotes appear to be limited to neuronal cells. Genetic disruption of the mouse Pfdn5 gene results in reduced formation of microtubules and microfilaments, leading to progressive neurodegeneration, hydrocephalus, and reproductive abnormalities. These results suggest that PFDN5 is required for normal sensory and neuronal development (Lee et al., 2011).

Endoplasmic reticulum molecular chaperones and neurodevelopmental disorders

Neurodevelopmental disorders (NDDs) refer to the abnormal development of the nervous system caused by inherited or acquired diseases, resulting in brain dysfunction. NDDs include intellectual disability (ID), autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and bipolar disorder (BD) (Rutter et al., 2006; Thapar et al., 2017; Ismail and Shapiro, 2019; Morris-Rosendahl and Crocq, 2020). At present, the global prevalence of unexplained ID is 2–3% (Olusanya et al., 2020), the prevalence of ASD is 1–2% (Baxter et al., 2015; Zablotsky et al., 2015), the prevalence of ADHD is 5–7.2% (Polanczyk et al., 2007, 2014; Sokolova et al., 2017; Wang T. et al., 2017), and the prevalence of BD is 1–4% (Merikangas et al., 2011). Numerous studies have shown that children with NDDs have a high incidence of mental health problems compared with normal children (Arim et al., 2015; Eyre et al., 2019). NDDs bring heavy economic and mental burdens to families and society, seriously affect the quality of life of patients and their families and represent a public health problem of high concern worldwide. The pathogenesis of NDDs is complex. Environmental risk factors, such as the inflammatory response, immune disorders and metabolic disorders, and genetic factors, such as neuronal dysfunction and chromosome deletion, are involved in the occurrence of NDDs (Bădescu et al., 2016). The abnormal expression of ER chaperone proteins can lead to the dys-regulation of neurodevelopmental processes and participate in the occurrence of many neurodevelopmental diseases.

Endoplasmic reticulum molecular chaperones and autism spectrum disorder

Autism spectrum disorder is a brain developmental disorder characterized by language disorders, social difficulties, and repetitive and stereotyped behaviors (Lai et al., 2014).

Calreticulin and autism spectrum disorder

Current studies have reported copy number variations (CNVs) in specific genes, and the ASD-related literature has cited the involvement of ER chaperone proteins. However, the molecular mechanisms are not well understood. For example, when studying the relationship among CD47 overexpression, brain overgrowth and 16p11.2 deletion syndrome, Li et al. found that ER chaperone CRT-mediated phagocytosis was related to the pathogenesis of ASD (Li et al., 2021). CNV at 16p11.2 has been implicated in neuropsychiatric disorders, such as ASD and schizophrenia (Kumar et al., 2008; Weiss et al., 2008; McCarthy et al., 2009; Zarrei et al., 2019). Carriers with 16p11.2 deletions tend to have macrocephaly (or enlarged brain), whereas carriers with 16p11.2 duplications often have microcephaly (Bartholomeusz et al., 2002; Hazlett et al., 2011; Maillard et al., 2015; Sacco et al., 2015). Human induced pluripotent stem cells (hiPSCs) from controls and subjects with 16p11.2 deletions and duplications were employed to understand the underlying mechanisms regulating brain overgrowth. CD47 (the “do not eat me” signal) was found to be overexpressed in cells with the 16p11.2 deletion vector, and CRT was also highly expressed. Cells with high CRT expression should be eliminated by immunophagocytosis, whereas cells escape immunophagocytosis due to high expression of CD47 (Oldenborg et al., 2000). The phagocytosis and CRT expression of hiPSCs with 16p11.2 deletion were restored to the control level when anti-CD47, a CD47 blocking agent, was applied (Li et al., 2021). This finding indicates that the normal phagocytosis mediated by CRT is affected in 16p11.2 null cells, and this mechanism may be involved in the pathogenesis of ASD.

Protein disulfide isomerase A1 and autism spectrum disorder

Lammert et al. found that increased PDIA1 was associated with ASD (Lammert et al., 2017). Studies have shown that RELN gene mutation can lead to ASD complications (Fatemi et al., 2005). In the ASD mouse model based on the RELN R2290C (Reelin mutant gene) (Iossifov et al., 2014; Wang et al., 2014; Lammert and Howell, 2016) mutation, PDIA1 expression was increased in the neurospheres of RELN R2290C heterozygous (+/-) as well as in the cerebellum of RELN Orleans (Orl) +/- mice. Reelin protein is highly expressed in the developing cerebral cortex and cerebellum and plays an important role in neuronal migration. As an ER-resident chaperone, PDIA1 can ensure the formation of correct disulfide bonds in nascent proteins (Parakh and Atkin, 2015), but its overexpression may cause neuropathological diseases (Perri et al., 2016; Zeeshan et al., 2016). This finding indicates that the increased expression of PDIA1 may be associated with the risk of ASD.

Sigma-1 receptor and autism spectrum disorder

Fragile X syndrome (FXS) is a disorder of synaptic development and dysfunction (Hagerman et al., 2009) and is the most prevalent genetic form of ID, ASD, and ADHD (Boyle and Kaufmann, 2010; Budimirovic and Kaufmann, 2011; Kaufmann et al., 2017). FXS mouse models recapitulate anxiety phenotypes similar to those observed in the clinic. Blarcamesine is a Sig-1R agonist (Villard et al., 2011), and the important role of Sig-1R in calcium homeostasis and synaptic function (Su et al., 2016; Schmidt and Kruse, 2019) makes blarcamesine a potential candidate for FXS. Blarcamesine has shown preliminary efficacy in patients with Alzheimer’s disease, Rett syndrome (RTT), synaptic neurodegeneration and NDDs (Hampel et al., 2020). Reyes et al. conducted research on the role of blarcamesine in FXS (Reyes et al., 2021). These researchers used the Fmr1 knockout FXS mouse model (Bakker et al., 1994; Mientjes et al., 2006; Dahlhaus, 2018) to evaluate the effect of blarcamesine on key cognitive and behavioral aspects that represent the FXS phenotype. When FXS mice were administered blarcamesine, two key neurobehavioral phenotypes, the open field test (hyperactivity) and contextual fear conditioning (associative learning), returned to normal.

Kaufmann et al. conducted further studies on the role of blarcamesine in RTT (Kaufmann et al., 2019). RTT is a progressive, non-inherited, X-linked neurodevelopmental disorder with an incidence of approximately 1 in 10,000 female births (Laurvick et al., 2006; Neul et al., 2010). Most patients carry a mutation in the methyl-CpG-binding protein 2 (MECP2) gene, which encodes a rich transcriptional regulator in the brain (Amir et al., 1999; Neul et al., 2014). The disorder is characterized by a variety of neurological impairments, particularly affecting cognition (i.e., developmental delay, ID, communication deficits), behavior, and motor and autonomic dysfunction (Neul et al., 2010; Kaufmann et al., 2016). No specific effective treatment is available for RTT, and treatment is mainly symptomatic. Using female Mecp2 mutant mice (Samaco et al., 2013; Lombardi et al., 2015; Tan and Zoghbi, 2019) as the research object, the authors and others administered the Sig-1R agonist blarcamesine and found that motor defects, acoustic starvation defects and visual defects were significantly improved. These data suggest that Sig-1Rs play an important role in FXS and in neurological disorders that are genetically characterized as FXS.

Endoplasmic reticulum molecular chaperones and intellectual disability

Intellectual disability (ID) is a common disorder of nervous system development that leads to intellectual disabilities. Various factors can cause ID, including loss of important synaptic function, abnormal neuronal morphological development, and neuronal migration and localization disorders (Kaufman et al., 2010; Ropers, 2010; Mehregan et al., 2016).

SIL1 and intellectual disability

Studies have shown that SIL1 gene mutations causes Marinesco-Sjögren syndrome (MSS), and it is the only gene that has been found to cause MSS. MSS is a rare autosomal recessive genetic disease. Clinical studies have found that approximately 90% of patients with MSS caused by SIL1 mutation present with moderate to severe ID, motor delay, congenital cataract, cerebellar atrophy, and other NDDs (Roos et al., 2014; Osborn et al., 2017). It has been well established that the decreased interaction between Bip and SIL1 or the loss of SIL1 function alone leads to the abnormal migration and localization of cortical neurons, representing a possible cause of ID (Krieger et al., 2013; Inaguma et al., 2014).

Calnexin and intellectual disability

In a study of mucopolysaccharidosis type II (MPS II), Osaki et al. demonstrated that CNX expression directly affects intellectual deficits caused by iduronate 2-sulfatase (IDS) mutations (Osaki et al., 2019). MPS II is one of the most common mucopolysaccharidoses (Wraith et al., 1987; Stapleton et al., 2018) and is caused by mutations in the gene encoding IDS (Wilson et al., 1990). The loss of IDS function leads to the accumulation of heparan sulfate and dermatan sulfate of glycosaminoglycans throughout the body, resulting in skeletal deformities, retardation, rigid joints, and thick skin (Ficicioglu et al., 2018). It was found that mutant IDS retained in the ER requires binding to CNX to achieve folding. Thus, CNX knockdown reduces the transport of mutant IDS from the ER to lysosome and its enzymatic activity. These studies indicate that proper folding by interaction with CNX ensures its functional activity. These findings reveal the existence of a role between IDS and CNX for the treatment of ID caused by MPSII and IDS mutations (Osaki et al., 2019).

Sigma-1 receptor and intellectual disability

α-thalassemia X-linked intellectual disability (ATR-X) syndrome is caused by mutations in ATRX (Gibbons et al., 1992, 1995). ATR-X syndrome is characterized by a variety of clinical manifestations, including severe ID, facial dysmorphism, genital abnormalities, and seizures (Gibbons et al., 2008). Similarly, ATR-X model mice lacking Atrx exon 2 (Nogami et al., 2011) show phenotypes similar to the symptoms of ID noted in humans, cognitive deficits (Kaufmann and Moser, 2000; Levenga and Willemsen, 2012), and abnormal dendritic formation (Shioda et al., 2011). Yamaguchi et al. investigated whether Sig-1R promotes the increased activity of neurotrophic factors, such as BDNF, to induce neuroprotection and nerve regeneration (Yamaguchi et al., 2018). They found that treatment with the Sig-1R activator SA4503 (Matsuno et al., 1996) reversed axonal development and dendritic spine abnormalities in primary cultured cortical neurons of ATR-X model mice. In addition, SA4503 treatment rescued the cognitive deficits noted in ATR-X model mice.

Protein disulfide isomerase family A member 3 and intellectual disability

Recessive gene mutations underlie many developmental disorders and often lead to disabling neurological problems (Martin et al., 2018). Bilches et al. conducted clinical and genetic studies on large close relatives with ID (Bilches Medinas et al., 2022). These researchers isolated a homozygous mutant of PDIA3, c.170G > A (p. Cys57Tyr or C57Y), from the genes of clinical patients with ID and determined that this disease was associated with PDIA3. PDIA3 is an oxidoreductase containing a thioredoxin-like domain that catalyzes the formation and isomerization of disulfide bonds in the ER and is associated with syndromic ID (Ellgaard and Ruddock, 2005). Experiments in zebrafish embryos demonstrated that the PDIA3C57Y mutation is pathogenic and causes developmental defects, such as axonal disorganization and skeletal abnormalities. Abnormal PDIA3C57Y expression in the hippocampus leads to impaired synaptic plasticity and memory consolidation (Bilches Medinas et al., 2022).

Endoplasmic reticulum molecular chaperones and bipolar disorder

Bipolar disorder is a common mental disorder characterized by recurrent episodes of mania, hypomania, and depression. BD is characterized by mood swings between elevated and depressed moods (Rosso et al., 2007). The exact mechanism of these mood swings remains unclear and needs to be further elucidated.

Binding immunoglobulin protein and bipolar disorder

There is increasing evidence from previous in vitro studies that the ER, as a protein folding factory, plays a major role in BD (So et al., 2007; Hayashi et al., 2009; Pfaffenseller et al., 2014). The role of the ER molecular chaperone Bip in BD diseases is more reflected in ER stress. ER stress activates the UPR (Zhang and Kaufman, 2008; van Schadewijk et al., 2012), which is partially impaired in BD (Pfaffenseller et al., 2014). Therefore, Bengesser et al. analyzed Bip and C/EBP homologous protein (CHOP) gene expression and X-box binding protein 1 (XBP1) splicing in the peripheral blood of BD patients and control study participants (Bengesser et al., 2018). They isolated RNA from fasting blood of BD patients and control study participants, reverse transcribed it into cDNA, and analyzed Bip and CHOP gene expression. The results significantly increased Bip gene expression in BD samples. In addition, valproate, an atypical antipsychotic drug, has been shown to play a neuroprotective role by increasing the expression of chaperone proteins that assist ER protein folding, such as CRT and Bip (Chen et al., 2000; Bown et al., 2002; Kim et al., 2005). This neuroprotective effect has been suggested to be potentially related to the pathophysiology of neuropsychiatric disorders, such as schizophrenia and BD (Aghajani et al., 2006). However, the role of the specific pathophysiology of this neurological disorder remains to be elucidated.

Endoplasmic reticulum molecular chaperones and attention-deficit hyperactivity disorder

Attention-deficit hyperactivity disorder is a syndrome characterized by inattention, hyperactivity, emotional impulsivity, and learning difficulties (Tripp and Wickens, 2009).

At present, there are few studies on the role of molecular chaperones in ADHD, and more relevant studies exist at the level of drug treatment targets. Methylphenidate (MPH) is a commonly used stimulant drug for ADHD (Capp et al., 2005; Arnsten, 2006). The symptoms of ADHD patients are mostly consistent with dysfunction in the pre-frontal cortex (PFC) (Barkley et al., 1992), a highly functional region that directs and organizes attention, thoughts, and emotions (Arnsten and Li, 2005). It has been demonstrated that low-dose MPH injection into the PFC can improve working memory performance (Arnsten and Dudley, 2005). High MPH doses can cause behavioral sensitization and a high risk of addiction (Amini et al., 2004). Sig-1R receptor proteins are highly distributed in the PFC, striatum and hippocampus. At the cellular level, Sig-1R is post-synaptic (Hayashi and Su, 2004) and is an excitatory target for the treatment of ADHD (e.g., cocaine) (Matsumoto et al., 2001; Maurice et al., 2002). MPH was found to increase NMDA receptor-mediated synaptic transmission, which was mediated by Sig-1R. Under the same dose of MPH stimulation, the NMDA-induced post-synaptic strength in the hippocampus of mice supplemented with the Sig-1R agonist PRE-084 was significantly higher than that of the control group (Motawe et al., 2020). Similarly, pretreatment with the Sig-1R antagonist BD1063 effectively prevented hyperactivity caused by MPH hyperactivity (Matsumoto et al., 1995), confirming the importance of Sig-1R receptors in excitatory synaptic transmission (Zhang C. L. et al., 2012). Therefore, the active use of Sig-1R receptor ligands in the treatment of ADHD and prevention of MPH-induced addiction may have unexpected effects.

Conclusion

A considerable amount of evidence indicates that ER chaperones play key roles in neural development through various processes, such as neuronal migration and localization, neuronal morphogenesis, and synaptic modification. There are two main mechanisms by which ER chaperones participate in the regulation of neural development: 1. ER chaperones directly act on specific developmental periods to regulate developmental stages. 2. ER chaperones indirectly regulate development by regulating the spatial and temporal expression of secreted proteins or central development-related receptor proteins. Of these methods, the indirect regulation mode mainly affects the secretory protein Reelin and membrane receptor proteins AMPA receptor, NMDA receptor and Wnt receptor. Bip protein maintains protein homeostasis under ER stress. In addition, the key effects of these partners in neurodevelopmental diseases also deserve our attention (Table 1). Bip, SIL1, and PDI-1 regulate neuronal migration. Bip, CNX, CRT and PFDN regulate early embryonic development. CNX, CRT and Sig-1R regulate neuronal morphogenesis and dendritic axon growth. Bip, CNX, and Sig-1R regulate synaptic function (Figure 1). These direct effects occur through membrane receptor-independent mechanism and are related to the regulation of ER calcium levels by ER chaperones. However, the direct mechanisms of action remain unclear and need to be further studied.

TABLE 1.

The role of Endoplasmic reticulum (ER) chaperones in neural development.

Protein Localization Development stage Neurodevelopmental disorders References
GRP78/Bip ER lumen
ER trans-membrane
Cell surface
Nucleus
Embryonic neurodevelopment
Neuronal migration
Synapse formation and plasticity
BD Chen et al., 2000; Abood et al., 2001; Bown et al., 2002; Nadarajah and Parnavelas, 2002; Kim et al., 2005; Aghajani et al., 2006; Luo et al., 2006; So et al., 2007; Mimura et al., 2008; Zhang and Kaufman, 2008; Hayashi et al., 2009; Rossi et al., 2010; van Schadewijk et al., 2012; Chiarlone et al., 2014; Jin et al., 2014, 2017; Pfaffenseller et al., 2014; Wang J. et al., 2017; Bengesser et al., 2018; Gómez-Almería et al., 2021
SIL1 ER lumen Neuronal migration ID Krieger et al., 2013; Inaguma et al., 2014; Roos et al., 2014; Osborn et al., 2017; Wang J. et al., 2017
Calnexin ER trans-membrane
Cell surface
Embryonic neurodevelopment
Axon/dendrite initiation
Synapse formation and plasticity
ID Wraith et al., 1987; Wilson et al., 1990; Tjoelker et al., 1994; Gloor et al., 2001; Denzel et al., 2002; Coe et al., 2008; Smith et al., 2008; Kraus et al., 2010; Itakura et al., 2013; Ficicioglu et al., 2018; Jung et al., 2018; Stapleton et al., 2018; Osaki et al., 2019
Calreticulin ER lumen
Cytosol
Cell surface
Embryonic neurodevelopment
Axon/dendrite initiation
Neuronal differentiation
ASD Solheim et al., 1997; Mesaeli et al., 1999; Oldenborg et al., 2000; Rauch et al., 2000; Bartholomeusz et al., 2002; Chao, 2003; Willis et al., 2005; Kumar et al., 2008; Weiss et al., 2008; McCarthy et al., 2009; Vuppalanchi et al., 2010; Hazlett et al., 2011; Shih et al., 2012; Maillard et al., 2015; Sacco et al., 2015; Lee et al., 2019; Zarrei et al., 2019; Pacheco et al., 2020; Pilquil et al., 2020; Li et al., 2021
PDI ER lumen
Cell surface
Neuronal migration ASD, ID Desai et al., 1988; Whangbo and Kenyon, 1999; Turano et al., 2002; Wilkinson and Gilbert, 2004; Ellgaard and Ruddock, 2005; Fatemi et al., 2005; Iossifov et al., 2014; Wang et al., 2014; Parakh and Atkin, 2015; Lammert and Howell, 2016; Perri et al., 2016; Zeeshan et al., 2016; Lammert et al., 2017; Martin et al., 2018; Torpe et al., 2019; Bilches Medinas et al., 2022
Sigma-1 Receptor ER trans-membrane Axon/dendrite initiation
Spine maturation
Synapse formation and plasticity
ASD, ID, ADHD Barkley et al., 1992; Gibbons et al., 1992, 1995, 2008; Bakker et al., 1994; Matsuno et al., 1996; Amir et al., 1999; Kaufmann and Moser, 2000; Matsumoto et al., 2001; Aydar et al., 2002; Maurice et al., 2002; Amini et al., 2004; Hayashi and Su, 2004; Rizzuto et al., 2004; Arnsten and Dudley, 2005; Arnsten and Li, 2005; Capp et al., 2005; Arnsten, 2006; Csordás et al., 2006; Laurvick et al., 2006; Mientjes et al., 2006; Szabadkai et al., 2006; Kann and Kovács, 2007; Fontanilla et al., 2009; Hagerman et al., 2009; Tsai et al., 2009; Zheng, 2009; Boyle and Kaufmann, 2010; Cárdenas et al., 2010; Neul et al., 2010, 2014; Su et al., 2010, 2016; Budimirovic and Kaufmann, 2011; Nogami et al., 2011; Ruscher et al., 2011, 2012; Shioda et al., 2011; Villard et al., 2011; Ishima and Hashimoto, 2012; Kourrich et al., 2012; Levenga and Willemsen, 2012; Zhang C. L. et al., 2012; Mori et al., 2013; Samaco et al., 2013; Ishima et al., 2014; Peviani et al., 2014; Robson et al., 2014; Lombardi et al., 2015; Kaufmann et al., 2016, 2017, 2019; Xavier et al., 2016; Fukunaga and Moriguchi, 2017; Dahlhaus, 2018; Yamaguchi et al., 2018; Ryskamp et al., 2019; Schmidt and Kruse, 2019; Tan and Zoghbi, 2019; Hampel et al., 2020; Motawe et al., 2020; Reyes et al., 2021; Dalwadi et al., 2022
Prefoldin ER lumen
Nucleus
Cytosol
Embryonic neurodevelopment N.D. Cao et al., 2008; Monzo et al., 2010; Lee et al., 2011; Delgehyr et al., 2012; Glover and Clark, 2015; Bertling and Hotulainen, 2017

FIGURE 1.

FIGURE 1

Endoplasmic reticulum (ER) molecular chaperones involved in neurodevelopment. ER molecular chaperones regulate central nervous development through two mechanisms: 1. ER chaperones directly act on specific developmental periods and regulate developmental stages. 2. ER chaperones indirectly act on secretory proteins or receptor proteins and regulate ER stress by ensuring protein homeostasis. CRT and Sig-1R regulate neuronal morphogenesis and dendritic axon growth (A); Bip, SIL1, and PDI-1 regulate cortical neuron migration (C); CRT regulates Ca2+ to guide NGF differentiation into mature neurons (D); Bip, CNX, and Sig-1R regulate synaptic function (B). Indirect regulation mainly affects the secreted protein Reelin and AMPA and NMDA membrane receptors (C), which act on the post-synaptic membrane and nerve migration. Bip proteins are involved in endoplasmic quality control and transport misfolded proteins for degradation, thereby maintaining protein homeostasis under ER stress conditions. Insert (a) CRT cooperates with CNX and PDIA3 to form the CNX/CRT cycle that controls protein folding within the ER. The CNX/CRT cycle can specifically recognize glycoproteins linked by N2 glycosidic bonds and regulate Ca2+ homeostasis and Ca2+ signaling processes in the ER. Insert (b) Bip is involved in a variety of ER functions dependent on ATP-induced conformational changes. The adenosine triphosphatase (ATPase) cycle of Bip is regulated by its co-chaperones of two families, namely, the ER-localized DnaJ-like proteins (ERdjs) and the nucleotide exchange factors (NEFs). ERdjs enables Bip to stably associate with its target protein. The NEF SIL1 then mediates the release of the target protein from the upper Bip and further folds to form the mature protein. Modified from Fucikova et al. (2021), Ichhaporia and Hendershot (2021).

In summary, considerable research on the function of ER molecular chaperones has been performed, and some progress has been made. However, some limitations remain. 1. ER molecular chaperones have specific expression sites in the early stage of neural development, and specific spatial and temporal patterns coincide with different stages of neural development. For example, Bip is involved in early embryonic development and is closely related to cortical neuronal migration. Sig-1R regulates neuronal morphogenesis and dendritic axon growth and are mainly localized in the hippocampus. Do these findings suggest that the functions of these molecular chaperones are focused at specific developmental sites at specific developmental times? 2. The mechanism by which ER chaperones affect central nervous system development is still not well defined. For example, Bip and SIL1 coregulate the coordination mechanism during central development. CNX regulates the specific regulatory processes of the NMDA receptor and AMPA receptor. Whether PDI-mediated Wnt protein-dependent disulfide bond formation affects other developmental processes in addition to migration remains unclear. As well characterized molecular ER chaperone, the role of GRP94 in protein folding and assembly as well as in cancer and related diseases has been widely studied (Fu and Lee, 2006; Pan et al., 2009). However, there are few studies on GRP94 in neural development, and further exploration is needed. 3. At present, studies on the role of molecular chaperones in developmental function are insufficient, and further studies on the functions of these molecular chaperones in different brain regions are needed. Finally, studies on the key role and induction mechanism of molecular chaperones in neurodevelopmental diseases are limited.

At present, neurodevelopmental diseases have become a problem of great concern. The complex etiology and specific pathogenesis have affected the health of numerous individuals. Determining whether it is possible to repair developmental defects by controlling the expression of chaperone proteins and subsequently treat developmental diseases is the focus of our research.

Author contributions

XZ and JZ: conceptualization and funding acquisition. HS, MWu, MWa, and XZ: writing—original draft preparation. HS, MWu, and XZ: writing—review and editing. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 31960168) which covered the open access publication fees and Sci-Tech Planning Project of Jiaxing, China (Grant No. 2021AY10049) which covered other expenses of the work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Abood M. E., Rizvi G., Sallapudi N., McAllister S. D. (2001). Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309 197–201. 10.1016/s0304-3940(01)02065-1 [DOI] [PubMed] [Google Scholar]
  2. Aghajani A., Rahimi A., Fadai F., Ebrahimi A., Najmabadi H., Ohadi M. (2006). A point mutation at the calreticulin gene core promoter conserved sequence in a case of schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B 294–295. 10.1002/ajmg.b.30300 [DOI] [PubMed] [Google Scholar]
  3. Amini B., Yang P. B., Swann A. C., Dafny N. (2004). Differential locomotor responses in male rats from three strains to acute methylphenidate. Int. J. Neurosci. 114 1063–1084. 10.1080/00207450490475526 [DOI] [PubMed] [Google Scholar]
  4. Amir R. E., Van den Veyver I. B., Wan M., Tran C. Q., Francke U., Zoghbi H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23 185–188. 10.1038/13810 [DOI] [PubMed] [Google Scholar]
  5. Apolloni S., Caputi F., Pignataro A., Amadio S., Fabbrizio P., Ammassari-Teule M., et al. (2019). Histamine is an inducer of the heat shock response in SOD1-G93A models of ALS. Int. J. Mol. Sci. 20:3793. 10.3390/ijms20153793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Arim R. G., Kohen D. E., Garner R. E., Lach L. M., Brehaut J. C., MacKenzie M. J., et al. (2015). Psychosocial functioning in children with neurodevelopmental disorders and externalizing behavior problems. Disabil. Rehabil. 37 345–354. 10.3109/09638288.2014.919361 [DOI] [PubMed] [Google Scholar]
  7. Arnsten A. F. (2006). Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31 2376–2383. 10.1038/sj.npp.1301164 [DOI] [PubMed] [Google Scholar]
  8. Arnsten A. F., Dudley A. G. (2005). Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav. Brain Funct. 1:2. 10.1186/1744-9081-1-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Arnsten A. F., Li B. M. (2005). Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57 1377–1384. 10.1016/j.biopsych.2004.08.019 [DOI] [PubMed] [Google Scholar]
  10. Aydar E., Palmer C. P., Klyachko V. A., Jackson M. B. (2002). The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34 399–410. 10.1016/s0896-6273(02)00677-3 [DOI] [PubMed] [Google Scholar]
  11. Bădescu G. M., Fîlfan M., Sandu R. E., Surugiu R., Ciobanu O., Popa-Wagner A. (2016). Molecular mechanisms underlying neurodevelopmental disorders, ADHD and autism. Rom. J. Morphol. Embryol. 57 361–366. [PubMed] [Google Scholar]
  12. Bagni C., Zukin R. S. (2019). A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron 101 1070–1088. 10.1016/j.neuron.2019.02.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bakker C. E., Verheij C., Willemsen R., van der Helm R., Oerlemans F., Vermey M., et al. (1994). Fmr1 knockout mice: A model to study fragile X mental retardation. The dutch-belgian fragile X consortium. Cell 78 23–33. [PubMed] [Google Scholar]
  14. Barkley R. A., Grodzinsky G., DuPaul G. J. (1992). Frontal lobe functions in attention deficit disorder with and without hyperactivity: A review and research report. J. Abnorm. Child Psychol. 20 163–188. 10.1007/BF00916547 [DOI] [PubMed] [Google Scholar]
  15. Bartholomeusz H. H., Courchesne E., Karns C. M. (2002). Relationship between head circumference and brain volume in healthy normal toddlers, children, and adults. Neuropediatrics 33 239–241. 10.1055/s-2002-36735 [DOI] [PubMed] [Google Scholar]
  16. Baxter A. J., Brugha T. S., Erskine H. E., Scheurer R. W., Vos T., Scott J. G. (2015). The epidemiology and global burden of autism spectrum disorders. Psychol. Med. 45 601–613. 10.1017/S003329171400172X [DOI] [PubMed] [Google Scholar]
  17. Beghi E., Chiò A., Couratier P., Esteban J., Hardiman O., Logroscino G., et al. (2011). The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 12 1–10. 10.3109/17482968.2010.502940 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Belmonte-Mateos C., Pujades C. (2022). From cell states to cell fates: How cell proliferation and neuronal differentiation are coordinated during embryonic development. Front. Neurosci. 15:781160. 10.3389/fnins.2021.781160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Bengesser S. A., Reininghaus E. Z., Dalkner N., Birner A., Hohenberger H., Queissner R., et al. (2018). Endoplasmic reticulum stress in bipolar disorder? – BiP and CHOP gene expression- and XBP1 splicing analysis in peripheral blood. Psychoneuroendocrinology 95 113–119. 10.1016/j.psyneuen.2018.05.029 [DOI] [PubMed] [Google Scholar]
  20. Bertling E., Hotulainen P. (2017). New waves in dendritic spine actin cytoskeleton: From branches and bundles to rings, from actin binding proteins to post-translational modifications. Mol. Cell. Neurosci. 84 77–84. 10.1016/j.mcn.2017.05.002 [DOI] [PubMed] [Google Scholar]
  21. Bilches Medinas D., Malik S., Yıldız-Bölükbaşı E., Borgonovo J., Saaranen M. J., Urra H., et al. (2022). Mutation in protein disulfide isomerase A3 causes neurodevelopmental defects by disturbing endoplasmic reticulum proteostasis. EMBO J. 41:e105531. 10.15252/embj.2020105531 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bocchi R., Egervari K., Carol-Perdiguer L., Viale B., Quairiaux C., De Roo M., et al. (2017). Perturbed Wnt signaling leads to neuronal migration delay, altered interhemispheric connections and impaired social behavior. Nat. Commun. 8:1158. 10.1038/s41467-017-01046-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Bose D., Chakrabarti A. (2017). Substrate specificity in the context of molecular chaperones. IUBMB Life 69 647–659. 10.1002/iub.1656 [DOI] [PubMed] [Google Scholar]
  24. Bostan A. C., Dum R. P., Strick P. L. (2018). Functional anatomy of basal ganglia circuits with the cerebral cortex and the cerebellum. Prog. Neurol. Surg. 33 50–61. 10.1159/000480748 [DOI] [PubMed] [Google Scholar]
  25. Bown C. D., Wang J. F., Chen B., Young L. T. (2002). Regulation of ER stress proteins by valproate: Therapeutic implications. Bipolar Disord. 4 145–151. 10.1034/j.1399-5618.2002.t01-1-40201.x [DOI] [PubMed] [Google Scholar]
  26. Boyle L., Kaufmann W. E. (2010). The behavioral phenotype of FMR1 mutations. Am. J. Med. Genet. C Semin. Med. Genet. 154C 469–476. 10.1002/ajmg.c.30277 [DOI] [PubMed] [Google Scholar]
  27. Bradke F., Fawcett J. W., Spira M. E. (2012). Assembly of a new growth cone after axotomy: The precursor to axon regeneration. Nat. Rev. Neurosci. 13 183–193. 10.1038/nrn3176 [DOI] [PubMed] [Google Scholar]
  28. Bramham C. R., Alme M. N., Bittins M., Kuipers S. D., Nair R. R., Pai B., et al. (2010). The Arc of synaptic memory. Exp. Brain Res. 200 125–140. 10.1007/s00221-009-1959-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Budimirovic D. B., Kaufmann W. E. (2011). What can we learn about autism from studying fragile X syndrome? Dev. Neurosci. 33 379–394. 10.1159/000330213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Buffington S. A., Huang W., Costa-Mattioli M. (2014). Translational control in synaptic plasticity and cognitive dysfunction. Annu. Rev. Neurosci. 37 17–38. 10.1146/annurev-neuro-071013-014100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Cao S., Carlesso G., Osipovich A. B., Llanes J., Lin Q., Hoek K. L., et al. (2008). Subunit 1 of the prefoldin chaperone complex is required for lymphocyte development and function. J. Immunol. 181 476–484. 10.4049/jimmunol.181.1.476 [DOI] [PubMed] [Google Scholar]
  32. Capp P. K., Pearl P. L., Conlon C. (2005). Methylphenidate HCl: Therapy for attention deficit hyperactivity disorder. Expert Rev. Neurother. 5 325–331. 10.1586/14737175.5.3.325 [DOI] [PubMed] [Google Scholar]
  33. Cárdenas C., Miller R. A., Smith I., Bui T., Molgó J., Müller M., et al. (2010). Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 142 270–283. 10.1016/j.cell.2010.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Carver J. A., Ecroyd H., Truscott R., Thorn D. C., Holt C. (2018). Proteostasis and the regulation of intra- and extracellular protein aggregation by ATP-independent molecular chaperones: Lens α-crystallins and milk caseins. Acc. Chem. Res. 51 745–752. 10.1021/acs.accounts.7b00250 [DOI] [PubMed] [Google Scholar]
  35. Castelo-Branco G., Wagner J., Rodriguez F. J., Kele J., Sousa K., Rawal N., et al. (2003). Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl. Acad. Sci. U.S.A. 100 12747–12752. 10.1073/pnas.1534900100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Caviness V. S., Jr. (1982). Neocortical histogenesis in normal and reeler mice: A developmental study based upon [3H]thymidine autoradiography. Brain Res. 256 293–302. 10.1016/0165-3806(82)90141-9 [DOI] [PubMed] [Google Scholar]
  37. Chao M. V. (2003). Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat. Rev. Neurosci. 4 299–309. 10.1038/nrn1078 [DOI] [PubMed] [Google Scholar]
  38. Chen B., Wang J. F., Young L. T. (2000). Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol. Psychiatry 48 658–664. 10.1016/s0006-3223(00)00878-7 [DOI] [PubMed] [Google Scholar]
  39. Chen B., Wu Z., Xu J., Xu Y. (2015). Calreticulin binds to fas ligand and inhibits neuronal cell apoptosis induced by ischemia-reperfusion injury. Biomed Res. Int. 2015:895284. 10.1155/2015/895284 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Chiarlone A., Bellocchio L., Blázquez C., Resel E., Soria-Gómez E., Cannich A., et al. (2014). A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U.S.A. 111 8257–8262. 10.1073/pnas.1400988111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Coe H., Bedard K., Groenendyk J., Jung J., Michalak M. (2008). Endoplasmic reticulum stress in the absence of calnexin. Cell Stress Chaperones 13 497–507. 10.1007/s12192-008-0049-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Correll R. N., Grimes K. M., Prasad V., Lynch J. M., Khalil H., Molkentin J. D. (2019). Overlapping and differential functions of ATF6α versus ATF6β in the mouse heart. Sci. Rep. 9:2059. 10.1038/s41598-019-39515-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Coudreuse D. Y., Roël G., Betist M. C., Destrée O., Korswagen H. C. (2006). Wnt gradient formation requires retromer function in Wnt-producing cells. Science 312 921–924. 10.1126/science.1124856 [DOI] [PubMed] [Google Scholar]
  44. Crelin E. S. (1974). Development of the nervous system. A logical approach to neuroanatomy. Clin. Symposia 26 1–32. [PubMed] [Google Scholar]
  45. Csordás G., Renken C., Várnai P., Walter L., Weaver D., Buttle K. F., et al. (2006). Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. 174 915–921. 10.1083/jcb.200604016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Cull-Candy S., Brickley S., Farrant M. (2001). NMDA receptor subunits: Diversity, development and disease. Curr. Opin. Neurobiol. 11 327–335. 10.1016/s0959-4388(00)00215-4 [DOI] [PubMed] [Google Scholar]
  47. Dahlhaus R. (2018). Of men and mice: Modeling the fragile X syndrome. Front. Mol. Neurosci. 11:41. 10.3389/fnmol.2018.00041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Dalwadi D. A., Kim S., Schetz J., Schreihofer D. A., Kim S. (2022). Brain-derived neurotrophic factor for high-throughput evaluation of selective sigma-1 receptor ligands. J. Pharmacol. Toxicol. Methods 113:107129. 10.1016/j.vascn.2021.107129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. DaSilva L. L., Wall M. J., P de Almeida L., Wauters S. C., Januário Y. C., Müller J., et al. (2016). Activity-regulated cytoskeleton-associated protein controls AMPAR endocytosis through a direct interaction with clathrin-adaptor protein 2. eNeuro 3 1–22. 10.1523/ENEURO.0144-15.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. de Montigny C., Monnet F. P., Fournier A., Debonnel G. (1992). Sigma ligands and neuropeptide Y selectively potentiate the NMDA response in the rat CA3 dorsal hippocampus: In vivo electrophysiological studies. Clin. Neuropharmacol. 15(Suppl. 1) 145A–146A. 10.1097/00002826-199201001-00078 [DOI] [PubMed] [Google Scholar]
  51. Delgehyr N., Wieland U., Rangone H., Pinson X., Mao G., Dzhindzhev N. S., et al. (2012). Drosophila Mgr, a Prefoldin subunit cooperating with von Hippel Lindau to regulate tubulin stability. Proc. Natl. Acad. Sci. U.S.A. 109 5729–5734. 10.1073/pnas.1108537109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Denzel A., Molinari M., Trigueros C., Martin J. E., Velmurgan S., Brown S., et al. (2002). Early postnatal death and motor disorders in mice congenitally deficient in calnexin expression. Mol. Cell. Biol. 22 7398–7404. 10.1128/MCB.22.21.7398-7404.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Desai C., Garriga G., McIntire S. L., Horvitz H. R. (1988). A genetic pathway for the development of the Caenorhabditis elegans HSN motor neurons. Nature 336 638–646. 10.1038/336638a0 [DOI] [PubMed] [Google Scholar]
  54. Devakumar D., Bamford A., Ferreira M. U., Broad J., Rosch R. E., Groce N., et al. (2018). Infectious causes of microcephaly: Epidemiology, pathogenesis, diagnosis, and management. Lancet Infect. Dis. 18 e1–e13. 10.1016/S1473-3099(17)30398-5 [DOI] [PubMed] [Google Scholar]
  55. Doyle S. M., Genest O., Wickner S. (2013). Protein rescue from aggregates by powerful molecular chaperone machines. Nat. Rev. Mol. Cell Biol. 14 617–629. 10.1038/nrm3660 [DOI] [PubMed] [Google Scholar]
  56. Ehlers M. D. (2000). Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 28 511–525. 10.1016/s0896-6273(00)00129-x [DOI] [PubMed] [Google Scholar]
  57. Ellgaard L., Ruddock L. W. (2005). The human protein disulphide isomerase family: Substrate interactions and functional properties. EMBO Rep. 6 28–32. 10.1038/sj.embor.7400311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Eyre O., Hughes R. A., Thapar A. K., Leibenluft E., Stringaris A., Davey Smith G., et al. (2019). Childhood neurodevelopmental difficulties and risk of adolescent depression: The role of irritability. J. Child Psychol. Psychiatry 60 866–874. 10.1111/jcpp.13053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Fatemi S. H., Snow A. V., Stary J. M., Araghi-Niknam M., Reutiman T. J., Lee S., et al. (2005). Reelin signaling is impaired in autism. Biol. Psychiatry 57 777–787. [DOI] [PubMed] [Google Scholar]
  60. Fernández-Fernández M. R., Valpuesta J. M. (2018). Hsp70 chaperone: A master player in protein homeostasis. F1000Res. 7 1–10. 10.12688/f1000research.15528.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Ficicioglu C., Giugliani R., Harmatz P., Mendelsohn N. J., Jego V., Parini R. (2018). Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the hunter outcome survey (HOS). Am. J. Med. Genet. A 176 301–310. 10.1002/ajmg.a.38551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Filareti M., Luotti S., Pasetto L., Pignataro M., Paolella K., Messina P., et al. (2017). Decreased levels of foldase and chaperone proteins are associated with an early-onset amyotrophic lateral sclerosis. Front. Mol. Neurosci. 10:99. 10.3389/fnmol.2017.00099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Fontanilla D., Johannessen M., Hajipour A. R., Cozzi N. V., Jackson M. B., Ruoho A. E. (2009). The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323 934–937. 10.1126/science.1166127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Freese J. L., Pino D., Pleasure S. J. (2010). Wnt signaling in development and disease. Neurobiol. Dis. 38 148–153. 10.1016/j.nbd.2009.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Freilich R., Arhar T., Abrams J. L., Gestwicki J. E. (2018). Protein-protein interactions in the molecular chaperone network. Acc. Chem. Res. 51 940–949. 10.1021/acs.accounts.8b00036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Fu Y., Lee A. S. (2006). Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol. Ther. 5 741–744. 10.4161/cbt.5.7.2970 [DOI] [PubMed] [Google Scholar]
  67. Fucikova J., Spisek R., Kroemer G., Galluzzi L. (2021). Calreticulin and cancer. Cell Res. 31 5–16. 10.1038/s41422-020-0383-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Fukunaga K., Moriguchi S. (2017). Stimulation of the sigma-1 receptor and the effects on neurogenesis and depressive behaviors in mice. Adv. Exp. Med. Biol. 964 201–211. 10.1007/978-3-319-50174-1_14 [DOI] [PubMed] [Google Scholar]
  69. Galligan J. J., Petersen D. R. (2012). The human protein disulfide isomerase gene family. Hum. Genomics 6:6. 10.1186/1479-7364-6-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Gerrow K., Triller A. (2010). Synaptic stability and plasticity in a floating world. Curr. Opin. Neurobiol. 20 631–639. 10.1016/j.conb.2010.06.010 [DOI] [PubMed] [Google Scholar]
  71. Gewirth D. T. (2016). Paralog specific Hsp90 inhibitors – a brief history and a bright future. Curr. Top. Med. Chem. 16 2779–2791. 10.2174/1568026616666160413141154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Ghashghaei H. T., Lai C., Anton E. S. (2007). Neuronal migration in the adult brain: Are we there yet? Nat. Rev. Neurosci. 8 141–151. 10.1038/nrn2074 [DOI] [PubMed] [Google Scholar]
  73. Gibbons R. J., Picketts D. J., Villard L., Higgs D. R. (1995). Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 80 837–845. 10.1016/0092-8674(95)90287-2 [DOI] [PubMed] [Google Scholar]
  74. Gibbons R. J., Suthers G. K., Wilkie A. O., Buckle V. J., Higgs D. R. (1992). X-linked alpha-thalassemia/mental retardation (ATR-X) syndrome: Localization to Xq12-q21.31 by X inactivation and linkage analysis. Am. J. Hum. Genet. 51 1136–1149. [PMC free article] [PubMed] [Google Scholar]
  75. Gibbons R. J., Wada T., Fisher C. A., Malik N., Mitson M. J., Steensma D. P., et al. (2008). Mutations in the chromatin-associated protein ATRX. Hum. Mutat. 29 796–802. 10.1002/humu.20734 [DOI] [PubMed] [Google Scholar]
  76. Gloor S. M., Wachtel M., Bolliger M. F., Ishihara H., Landmann R., Frei K. (2001). Molecular and cellular permeability control at the blood-brain barrier. Brain Res. 36 258–264. 10.1016/s0165-0173(01)00102-3 [DOI] [PubMed] [Google Scholar]
  77. Glover D. J., Clark D. S. (2015). Oligomeric assembly is required for chaperone activity of the filamentous γ-prefoldin. FEBS J. 282 2985–2997. 10.1111/febs.13341 [DOI] [PubMed] [Google Scholar]
  78. Gómez-Almería M., Burgaz S., Costas-Insua C., Rodríguez-Cueto C., Santos-García I., Rodríguez-Crespo I., et al. (2021). BiP heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis. Int. J. Mol. Sci. 22:12533. 10.3390/ijms222212533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Guerrini R., Dobyns W. B. (2014). Malformations of cortical development: Clinical features and genetic causes. Lancet Neurol. 13 710–726. 10.1016/S1474-4422(14)70040-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Guo C., Ma Y. Y. (2021). Calcium permeable-AMPA receptors and excitotoxicity in neurological disorders. Front. Neural Circuits 15:711564. 10.3389/fncir.2021.711564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Hagerman R. J., Berry-Kravis E., Kaufmann W. E., Ono M. Y., Tartaglia N., Lachiewicz A., et al. (2009). Advances in the treatment of fragile X syndrome. Pediatrics 123 378–390. 10.1542/peds.2008-0317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Hampel H., Williams C., Etcheto A., Goodsaid F., Parmentier F., Sallantin J., et al. (2020). A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimers Dement. 6:e12013. 10.1002/trc2.12013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Hanner M., Moebius F. F., Flandorfer A., Knaus H. G., Striessnig J., Kempner E., et al. (1996). Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U.S.A. 93 8072–8077. 10.1073/pnas.93.15.8072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Hayashi A., Kasahara T., Kametani M., Toyota T., Yoshikawa T., Kato T. (2009). Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from patients with bipolar disorder. Int. J. Neuropsychopharmacol. 12 33–43. 10.1017/S1461145708009358 [DOI] [PubMed] [Google Scholar]
  85. Hayashi T., Su T. P. (2004). Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs 18 269–284. 10.2165/00023210-200418050-00001 [DOI] [PubMed] [Google Scholar]
  86. Hayashi T., Su T. P. (2007). Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131 596–610. 10.1016/j.cell.2007.08.036 [DOI] [PubMed] [Google Scholar]
  87. Hazlett H. C., Poe M. D., Gerig G., Styner M., Chappell C., Smith R. G., et al. (2011). Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch. Gen. Psychiatry 68 467–476. 10.1001/archgenpsychiatry.2011.39 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Helenius A., Aebi M. (2001). Intracellular functions of N-linked glycans. Science 291 2364–2369. 10.1126/science.291.5512.2364 [DOI] [PubMed] [Google Scholar]
  89. Hendershot L., Wei J., Gaut J., Melnick J., Aviel S., Argon Y. (1996). Inhibition of immunoglobulin folding and secretion by dominant negative BiP ATPase mutants. Proc. Natl. Acad. Sci. U.S.A. 93 5269–5274. 10.1073/pnas.93.11.5269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Henley J. M., Wilkinson K. A. (2016). Synaptic AMPA receptor composition in development, plasticity and disease. Nat. Rev. Neurosci. 17 337–350. 10.1038/nrn.2016.37 [DOI] [PubMed] [Google Scholar]
  91. Hilliard M. A., Bargmann C. I. (2006). Wnt signals and frizzled activity orient anterior-posterior axon outgrowth in C. elegans. Dev. Cell 10 379–390. 10.1016/j.devcel.2006.01.013 [DOI] [PubMed] [Google Scholar]
  92. Hinata M., Matsuoka I., Iwamoto T., Watanabe Y., Kimura J. (2007). Mechanism of Na+/Ca2+ exchanger activation by hydrogen peroxide in guinea-pig ventricular myocytes. J. Pharmacol. Sci. 103 283–292. 10.1254/jphs.fp0060015 [DOI] [PubMed] [Google Scholar]
  93. Hoter A., El-Sabban M. E., Naim H. Y. (2018). The HSP90 family: Structure, regulation, function, and implications in health and disease. Int. J. Mol. Sci. 19:2560. 10.3390/ijms19092560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Ichhaporia V. P., Hendershot L. M. (2021). Role of the HSP70 co-chaperone sil1 in health and disease. Int. J. Mol. Sci. 22:1564. 10.3390/ijms22041564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Inaguma Y., Hamada N., Tabata H., Iwamoto I., Mizuno M., Nishimura Y. V., et al. (2014). SIL1, a causative cochaperone gene of marinesco-söjgren syndrome, plays an essential role in establishing the architecture of the developing cerebral cortex. EMBO Mol. Med. 6 414–429. 10.1002/emmm.201303069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Iossifov I., O’Roak B. J., Sanders S. J., Ronemus M., Krumm N., Levy D., et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. Nature 515 216–221. 10.1038/nature13908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Ishima T., Hashimoto K. (2012). Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: The role of sigma-1 and IP3 receptors. PLoS One 7:e37989. 10.1371/journal.pone.0037989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Ishima T., Fujita Y., Hashimoto K. (2014). Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur. J. Pharmacol. 727 167–173. 10.1016/j.ejphar.2014.01.064 [DOI] [PubMed] [Google Scholar]
  99. Ismail F. Y., Shapiro B. K. (2019). What are neurodevelopmental disorders? Curr. Opin. Neurol. 32 611–616. 10.1097/WCO.0000000000000710 [DOI] [PubMed] [Google Scholar]
  100. Itakura M., Tsujimura J., Yamamori S., Ohkido T., Takahashi M. (2013). NMDA receptor-dependent recruitment of calnexin to the neuronal plasma membrane. Neurosci. Lett. 550 173–178. 10.1016/j.neulet.2013.06.064 [DOI] [PubMed] [Google Scholar]
  101. Jiang Y. S., Xu Z. H. (2019). Brain developmental diseases and pathogenic mechanisms. Hereditas 41 801–815. 10.16288/j.yczz.19-133 [DOI] [PubMed] [Google Scholar]
  102. Jin H., Komita M., Aoe T. (2017). The role of BiP retrieval by the KDEL receptor in the early secretory pathway and its effect on protein quality control and neurodegeneration. Front. Mol. Neurosci. 10:222. 10.3389/fnmol.2017.00222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Jin H., Mimura N., Kashio M., Koseki H., Aoe T. (2014). Late-onset of spinal neurodegeneration in knock-in mice expressing a mutant BiP. PLoS One 9:e112837. 10.1371/journal.pone.0112837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Jossin Y., Goffinet A. M. (2007). Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol. Cell. Biol. 27 7113–7124. 10.1128/MCB.00928-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Jung J., Eggleton P., Robinson A., Wang J., Gutowski N., Holley J., et al. (2018). Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight 3:e98410. 10.1172/jci.insight.98410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Kadoyama K., Matsuura K., Takano M., Maekura K., Inoue Y., Matsuyama S. (2019). Changes in the expression of prefoldin subunit 5 depending on synaptic plasticity in the mouse hippocampus. Neurosci. Lett. 712:134484. 10.1016/j.neulet.2019.134484 [DOI] [PubMed] [Google Scholar]
  107. Kann O., Kovács R. (2007). Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 292 C641–C657. 10.1152/ajpcell.00222.2006 [DOI] [PubMed] [Google Scholar]
  108. Kaufman L., Ayub M., Vincent J. B. (2010). The genetic basis of non-syndromic intellectual disability: A review. J. Neurodev. Disord. 2 182–209. 10.1007/s11689-010-9055-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Kaufmann W. E., Moser H. W. (2000). Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 10 981–991. 10.1093/cercor/10.10.981 [DOI] [PubMed] [Google Scholar]
  110. Kaufmann W. E., Kidd S. A., Andrews H. F., Budimirovic D. B., Esler A., Haas-Givler B., et al. (2017). Autism spectrum disorder in fragile X syndrome: Cooccurring conditions and current treatment. Pediatrics 139(Suppl. 3) S194–S206. 10.1542/peds.2016-1159F [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Kaufmann W. E., Sprouse J., Rebowe N., Hanania T., Klamer D., Missling C. U. (2019). ANAVEX§2-73 (blarcamesine), a sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of rett syndrome. Pharmacol. Biochem. Behav. 187:172796. 10.1016/j.pbb.2019.172796 [DOI] [PubMed] [Google Scholar]
  112. Kaufmann W. E., Stallworth J. L., Everman D. B., Skinner S. A. (2016). Neurobiologically-based treatments in rett syndrome: Opportunities and challenges. Expert Opin. Orphan Drugs 4 1043–1055. 10.1080/21678707.2016.1229181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Kessels H. W., Malinow R. (2009). Synaptic AMPA receptor plasticity and behavior. Neuron 61 340–350. 10.1016/j.neuron.2009.01.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Kim A. J., Shi Y., Austin R. C., Werstuck G. H. (2005). Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 118(Pt 1) 89–99. 10.1242/jcs.01562 [DOI] [PubMed] [Google Scholar]
  115. Kimura K., Jin H., Ogawa M., Aoe T. (2008). Dysfunction of the ER chaperone BiP accelerates the renal tubular injury. Biochem. Biophys. Res. Commun. 366 1048–1053. 10.1016/j.bbrc.2007.12.098 [DOI] [PubMed] [Google Scholar]
  116. Korb E., Finkbeiner S. (2011). Arc in synaptic plasticity: From gene to behavior. Trends Neurosci. 34 591–598. 10.1016/j.tins.2011.08.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Kourrich S., Su T. P., Fujimoto M., Bonci A. (2012). The sigma-1 receptor: Roles in neuronal plasticity and disease. Trends Neurosci. 35 762–771. 10.1016/j.tins.2012.09.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Kraus A., Groenendyk J., Bedard K., Baldwin T. A., Krause K. H., Dubois-Dauphin M., et al. (2010). Calnexin deficiency leads to dysmyelination. J. Biol. Chem. 285 18928–18938. 10.1074/jbc.M110.107201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Krieger M., Roos A., Stendel C., Claeys K. G., Sonmez F. M., Baudis M., et al. (2013). SIL1 mutations and clinical spectrum in patients with marinesco-sjogren syndrome. Brain 136(Pt 12) 3634–3644. 10.1093/brain/awt283 [DOI] [PubMed] [Google Scholar]
  120. Kumar R. A., KaraMohamed S., Sudi J., Conrad D. F., Brune C., Badner J. A., et al. (2008). Recurrent 16p11.2 microdeletions in autism. Hum. Mol. Genet. 17 628–638. 10.1093/hmg/ddm376 [DOI] [PubMed] [Google Scholar]
  121. Kwan K. Y., Sestan N., Anton E. S. (2012). Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. Development 139 1535–1546. 10.1242/dev.069963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Kwon O. C., Lee E. J., Lee J. Y., Youn J., Kim T. H., Hong S., et al. (2019). Prefoldin 5 and anti-prefoldin 5 antibodies as biomarkers for uveitis in ankylosing spondylitis. Front. Immunol. 10:384. 10.3389/fimmu.2019.00384 [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Lai M. C., Lombardo M. V., Baron-Cohen S. (2014). Autism. Lancet 383 896–910. 10.1016/S0140-6736(13)61539-1 [DOI] [PubMed] [Google Scholar]
  124. Lammert D. B., Howell B. W. (2016). RELN mutations in autism spectrum disorder. Front. Cell. Neurosci. 10:84. 10.3389/fncel.2016.00084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Lammert D. B., Middleton F. A., Pan J., Olson E. C., Howell B. W. (2017). The de novo autism spectrum disorder RELN R2290C mutation reduces reelin secretion and increases protein disulfide isomerase expression. J. Neurochem. 142 89–102. 10.1111/jnc.14045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Laurvick C. L., de Klerk N., Bower C., Christodoulou J., Ravine D., Ellaway C., et al. (2006). Rett syndrome in Australia: A review of the epidemiology. J. Pediatr. 148 347–352. 10.1016/j.jpeds.2005.10.037 [DOI] [PubMed] [Google Scholar]
  127. Lee A. C., Shih Y. Y., Zhou F., Chao T. C., Lee H., Liao Y. F., et al. (2019). Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma. J. Mol. Med. 97 325–339. 10.1007/s00109-018-1730-x [DOI] [PubMed] [Google Scholar]
  128. Lee Y., Smith R. S., Jordan W., King B. L., Won J., Valpuesta J. M., et al. (2011). Prefoldin 5 is required for normal sensory and neuronal development in a murine model. J. Biol. Chem. 286 726–736. 10.1074/jbc.M110.177352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Leemhuis J., Bock H. H. (2011). Reelin modulates cytoskeletal organization by regulating Rho GTPases. Commun. Integr. Biol. 4 254–257. 10.4161/cib.4.3.14890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Levenga J., Willemsen R. (2012). Perturbation of dendritic protrusions in intellectual disability. Prog. Brain Res. 197 153–168. 10.1016/B978-0-444-54299-1.00008-X [DOI] [PubMed] [Google Scholar]
  131. Li G., Pleasure S. J. (2014). The development of hippocampal cellular assemblies. Wiley Interdiscip. Rev. Dev. Biol. 3 165–177. 10.1002/wdev.127 [DOI] [PubMed] [Google Scholar]
  132. Li H. D., Liu W. X., Michalak M. (2011). Enhanced clathrin-dependent endocytosis in the absence of calnexin. PLoS One 6:e21678. 10.1371/journal.pone.0021678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Li J., Brickler T., Banuelos A., Marjon K., Shcherbina A., Banerjee S., et al. (2021). Overexpression of CD47 is associated with brain overgrowth and 16p11.2 deletion syndrome. Proc. Natl. Acad. Sci. U.S.A. 118:e2005483118. 10.1073/pnas.2005483118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Lièvremont J. P., Rizzuto R., Hendershot L., Meldolesi J. (1997). BiP, a major chaperone protein of the endoplasmic reticulum lumen, plays a direct and important role in the storage of the rapidly exchanging pool of Ca2+. J. Biol. Chem. 272 30873–30879. 10.1074/jbc.272.49.30873 [DOI] [PubMed] [Google Scholar]
  135. Liu X. B., Murray K. D., Jones E. G. (2004). Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J. Neurosci. 24 8885–8895. 10.1523/JNEUROSCI.2476-04.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Lombardi L. M., Baker S. A., Zoghbi H. Y. (2015). MECP2 disorders: From the clinic to mice and back. J. Clin. Investig. 125 2914–2923. 10.1172/JCI78167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Lopez de Armentia M., Sah P. (2003). Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala. J. Neurosci. 23 6876–6883. 10.1523/JNEUROSCI.23-17-06876.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Luo S., Mao C., Lee B., Lee A. S. (2006). GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol. Cell. Biol. 26 5688–5697. 10.1128/MCB.00779-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Lynch J. M., Maillet M., Vanhoutte D., Schloemer A., Sargent M. A., Blair N. S., et al. (2012). A thrombospondin-dependent pathway for a protective ER stress response. Cell 149 1257–1268. 10.1016/j.cell.2012.03.050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Ma F. H., Li C., Liu Y., Shi L. (2020). Mimicking molecular chaperones to regulate protein folding. Adv. Mater. 32:e1805945. 10.1002/adma.201805945 [DOI] [PubMed] [Google Scholar]
  141. MacDonald B. T., Hien A., Zhang X., Iranloye O., Virshup D. M., Waterman M. L., et al. (2014). Disulfide bond requirements for active Wnt ligands. J. Biol. Chem. 289 18122–18136. 10.1074/jbc.M114.575027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Maillard A. M., Ruef A., Pizzagalli F., Migliavacca E., Hippolyte L., Adaszewski S., et al. (2015). The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol. Psychiatry 20 140–147. 10.1038/mp.2014.145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Marín O., Valiente M., Ge X., Tsai L. H. (2010). Guiding neuronal cell migrations. Cold Spring Harb. Perspect. Biol. 2:a001834. 10.1101/cshperspect.a001834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Martin H. C., Jones W. D., McIntyre R., Sanchez-Andrade G., Sanderson M., Stephenson J. D., et al. (2018). Quantifying the contribution of recessive coding variation to developmental disorders. Science 362 1161–1164. 10.1126/science.aar6731 [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Matsumoto R. R., Bowen W. D., Tom M. A., Vo V. N., Truong D. D., De Costa B. R. (1995). Characterization of two novel sigma receptor ligands: Antidystonic effects in rats suggest sigma receptor antagonism. Eur. J. Pharmacol. 280 301–310. 10.1016/0014-2999(95)00208-3 [DOI] [PubMed] [Google Scholar]
  146. Matsumoto R. R., Hewett K. L., Pouw B., Bowen W. D., Husbands S. M., Cao J. J., et al. (2001). Rimcazole analogs attenuate the convulsive effects of cocaine: Correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 41 878–886. 10.1016/s0028-3908(01)00116-2 [DOI] [PubMed] [Google Scholar]
  147. Matsuno K., Nakazawa M., Okamoto K., Kawashima Y., Mita S. (1996). Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur. J. Pharmacol. 306 271–279. 10.1016/0014-2999(96)00201-4 [DOI] [PubMed] [Google Scholar]
  148. Maurice T., Martin-Fardon R., Romieu P., Matsumoto R. R. (2002). Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci. Biobehav. Rev. 26 499–527. 10.1016/s0149-7634(02)00017-9 [DOI] [PubMed] [Google Scholar]
  149. Mayer M. P., Gierasch L. M. (2019). Recent advances in the structural and mechanistic aspects of Hsp70 molecular chaperones. J. Biol. Chem. 294 2085–2097. 10.1074/jbc.REV118.002810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. McCarthy S. E., Makarov V., Kirov G., Addington A. M., McClellan J., Yoon S., et al. (2009). Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 41 1223–1227. 10.1038/ng.474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. McCracken K. A., Bowen W. D., de Costa B. R., Matsumoto R. R. (1999). Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol. 370 225–232. 10.1016/s0014-2999(99)00113-2 [DOI] [PubMed] [Google Scholar]
  152. Mehregan H., Najmabadi H., Kahrizi K. (2016). Genetic studies in intellectual disability and behavioral impairment. Arch. Iran. Med. 19 363–375. [PubMed] [Google Scholar]
  153. Merikangas K. R., Jin R., He J. P., Kessler R. C., Lee S., Sampson N. A., et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 68 241–251. 10.1001/archgenpsychiatry.2011.12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Merlos M., Romero L., Zamanillo D., Plata-Salamán C., Vela J. M. (2017). Sigma-1 receptor and pain. Handb. Exp. Pharmacol. 244 131–161. 10.1007/164_2017_9 [DOI] [PubMed] [Google Scholar]
  155. Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K. H., et al. (1999). Calreticulin is essential for cardiac development. J. Cell Biol. 144 857–868. 10.1083/jcb.144.5.857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Michalak M., Corbett E. F., Mesaeli N., Nakamura K., Opas M. (1999). Calreticulin: One protein, one gene, many functions. Biochem. J. 344(Pt 2) 281–292. [PMC free article] [PubMed] [Google Scholar]
  157. Michalak M., Milner R. E., Burns K., Opas M. (1992). Calreticulin. Biochem. J. 285(Pt 3) 681–692. 10.1042/bj2850681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Mientjes E. J., Nieuwenhuizen I., Kirkpatrick L., Zu T., Hoogeveen-Westerveld M., Severijnen L., et al. (2006). The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol. Dis. 21 549–555. 10.1016/j.nbd.2005.08.019 [DOI] [PubMed] [Google Scholar]
  159. Miller D. J., Fort P. E. (2018). Heat shock proteins regulatory role in neurodevelopment. Front. Neurosci. 12:821. 10.3389/fnins.2018.00821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Mimura N., Yuasa S., Soma M., Jin H., Kimura K., Goto S., et al. (2008). Altered quality control in the endoplasmic reticulum causes cortical dysplasia in knock-in mice expressing a mutant BiP. Mol. Cell. Biol. 28 293–301. 10.1128/MCB.00473-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Monnet F. P., de Costa B. R., Bowen W. D. (1996). Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Br. J. Pharmacol. 119 65–72. 10.1111/j.1476-5381.1996.tb15678.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Monnet F. P., Debonnel G., Bergeron R., Gronier B., de Montigny C. (1994). The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurons are differentially affected by pertussin toxin. Br. J. Pharmacol. 112 709–715. 10.1111/j.1476-5381.1994.tb13134.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Monzo K., Dowd S. R., Minden J. S., Sisson J. C. (2010). Proteomic analysis reveals CCT is a target of Fragile X mental retardation protein regulation in Drosophila. Dev. Biol. 340 408–418. 10.1016/j.ydbio.2010.01.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Moon L. D., Xiong F. (2022). Mechanics of neural tube morphogenesis. Semin. Cell Dev. Biol. 130 56–69. 10.1016/j.semcdb.2021.09.009 [DOI] [PubMed] [Google Scholar]
  165. Mori T., Hayashi T., Hayashi E., Su T. P. (2013). Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS One 8:e76941. 10.1371/journal.pone.0076941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Morris-Rosendahl D. J., Crocq M. A. (2020). Neurodevelopmental disorders-the history and future of a diagnostic concept. Dialogues Clin. Neurosci. 22 65–72. 10.31887/DCNS.2020.22.1/macrocq [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Motawe Z. Y., Abdelmaboud S. S., Cuevas J., Breslin J. W. (2020). PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation. Int. J. Biochem. Cell Biol. 126:105803. 10.1016/j.biocel.2020.105803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Munji R. N., Choe Y., Li G., Siegenthaler J. A., Pleasure S. J. (2011). Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. J. Neurosci. 31 1676–1687. 10.1523/JNEUROSCI.5404-10.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Myrum C., Soulé J., Bittins M., Cavagnini K., Goff K., Ziemek S. K., et al. (2017). Arc Interacts with the integral endoplasmic reticulum protein, calnexin. Front. Cell. Neurosci. 11:294. 10.3389/fncel.2017.00294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Nadarajah B., Parnavelas J. G. (2002). Modes of neuronal migration in the developing cerebral cortex. Nat. Rev. Neurosci. 3 423–432. 10.1038/nrn845 [DOI] [PubMed] [Google Scholar]
  171. Nase G., Weishaupt J., Stern P., Singer W., Monyer H. (1999). Genetic and epigenetic regulation of NMDA receptor expression in the rat visual cortex. Eur. J. Neurosci. 11 4320–4326. 10.1046/j.1460-9568.1999.00859.x [DOI] [PubMed] [Google Scholar]
  172. Neul J. L., Kaufmann W. E., Glaze D. G., Christodoulou J., Clarke A. J., Bahi-Buisson N., et al. (2010). Rett syndrome: Revised diagnostic criteria and nomenclature. Ann. Neurol. 68 944–950. 10.1002/ana.22124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Neul J. L., Lane J. B., Lee H. S., Geerts S., Barrish J. O., Annese F., et al. (2014). Developmental delay in Rett syndrome: Data from the natural history study. J. Neurodev. Disord. 6:20. 10.1186/1866-1955-6-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Newpher T. M., Ehlers M. D. (2008). Glutamate receptor dynamics in dendritic microdomains. Neuron 58 472–497. 10.1016/j.neuron.2008.04.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Ni M., Lee A. S. (2007). ER chaperones in mammalian development and human diseases. FEBS Lett. 581 3641–3651. 10.1016/j.febslet.2007.04.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Nikolaienko O., Eriksen M. S., Patil S., Bito H., Bramham C. R. (2017). Stimulus-evoked ERK-dependent phosphorylation of activity-regulated cytoskeleton-associated protein (Arc) regulates its neuronal subcellular localization. Neuroscience 360 68–80. 10.1016/j.neuroscience.2017.07.026 [DOI] [PubMed] [Google Scholar]
  177. Nimchinsky E. A., Sabatini B. L., Svoboda K. (2002). Structure and function of dendritic spines. Annu. Rev. Physiol. 64 313–353. 10.1146/annurev.physiol.64.081501.160008 [DOI] [PubMed] [Google Scholar]
  178. Nishimura Y. V., Shinoda T., Inaguma Y., Ito H., Nagata K. (2012). Application of in utero electroporation and live imaging in the analyses of neuronal migration during mouse brain development. Med. Mol. Morphol. 45 1–6. 10.1007/s00795-011-0557-0 [DOI] [PubMed] [Google Scholar]
  179. Niu S., Renfro A., Quattrocchi C. C., Sheldon M., D’Arcangelo G. (2004). Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron 41 71–84. 10.1016/s0896-6273(03)00819-5 [DOI] [PubMed] [Google Scholar]
  180. Niu S., Yabut O., D’Arcangelo G. (2008). The reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J. Neurosci. 28 10339–10348. 10.1523/JNEUROSCI.1917-08.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Nogami T., Beppu H., Tokoro T., Moriguchi S., Shioda N., Fukunaga K., et al. (2011). Reduced expression of the ATRX gene, a chromatin-remodeling factor, causes hippocampal dysfunction in mice. Hippocampus 21 678–687. 10.1002/hipo.20782 [DOI] [PubMed] [Google Scholar]
  182. Oldenborg P. A., Zheleznyak A., Fang Y. F., Lagenaur C. F., Gresham H. D., Lindberg F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science 288 2051–2054. 10.1126/science.288.5473.2051 [DOI] [PubMed] [Google Scholar]
  183. Olusanya B. O., Wright S. M., Nair M., Boo N. Y., Halpern R., Kuper H., et al. (2020). Global burden of childhood epilepsy, intellectual disability, and sensory impairments. Pediatrics 146:e20192623. 10.1542/peds.2019-2623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Omotade O. F., Rui Y., Lei W., Yu K., Hartzell H. C., Fowler V. M., et al. (2018). Tropomodulin Isoform-specific regulation of dendrite development and synapse formation. J. Neurosci. 38 10271–10285. 10.1523/JNEUROSCI.3325-17.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Osaki Y., Matsuhisa K., Che W., Kaneko M., Asada R., Masaki T., et al. (2019). Calnexin promotes the folding of mutant iduronate 2-sulfatase related to mucopolysaccharidosis type II. Biochem. Biophys. Res. Commun. 514 217–223. 10.1016/j.bbrc.2019.04.115 [DOI] [PubMed] [Google Scholar]
  186. Osborn D., Pond H. L., Mazaheri N., Dejardin J., Munn C. J., Mushref K., et al. (2017). Mutations in INPP5K cause a form of congenital muscular dystrophy overlapping marinesco-sjögren syndrome and dystroglycanopathy. Am. J. Hum. Genet. 100 537–545. 10.1016/j.ajhg.2017.01.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Otero J. H., Lizák B., Hendershot L. M. (2010). Life and death of a BiP substrate. Semin. Cell Dev. Biol. 21 472–478. 10.1016/j.semcdb.2009.12.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  188. Pabba M., Wong A. Y., Ahlskog N., Hristova E., Biscaro D., Nassrallah W., et al. (2014). NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J. Neurosci. 34 11325–11338. 10.1523/JNEUROSCI.0458-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Pacheco A., Merianda T. T., Twiss J. L., Gallo G. (2020). Mechanism and role of the intra-axonal calreticulin translation in response to axonal injury. Exp. Neurol. 323:113072. 10.1016/j.expneurol.2019.113072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Pan C. L., Howell J. E., Clark S. G., Hilliard M., Cordes S., Bargmann C. I., et al. (2006). Multiple Wnts and frizzled receptors regulate anteriorly directed cell and growth cone migrations in Caenorhabditis elegans. Dev. Cell 10 367–377. 10.1016/j.devcel.2006.02.010 [DOI] [PubMed] [Google Scholar]
  191. Pan Z., Erkan M., Streit S., Friess H., Kleeff J. (2009). Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. Int. J. Oncol. 35 823–828. 10.3892/ijo_00000395 [DOI] [PubMed] [Google Scholar]
  192. Parakh S., Atkin J. D. (2015). Novel roles for protein disulphide isomerase in disease states: A double edged sword? Front. Cell Dev. Biol. 3:30. 10.3389/fcell.2015.00030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  193. Penke B., Fulop L., Szucs M., Frecska E. (2018). The role of sigma-1 receptor, an intracellular chaperone in neurodegenerative diseases. Curr. Neuropharmacol. 16 97–116. 10.2174/1570159X15666170529104323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Perri E. R., Thomas C. J., Parakh S., Spencer D. M., Atkin J. D. (2016). The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration. Front. Cell Dev. Biol. 3:80. 10.3389/fcell.2015.00080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Peviani M., Salvaneschi E., Bontempi L., Petese A., Manzo A., Rossi D., et al. (2014). Neuroprotective effects of the sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol. Dis. 62 218–232. 10.1016/j.nbd.2013.10.010 [DOI] [PubMed] [Google Scholar]
  196. Pfaffenseller B., Wollenhaupt-Aguiar B., Fries G. R., Colpo G. D., Burque R. K., Bristot G., et al. (2014). Impaired endoplasmic reticulum stress response in bipolar disorder: Cellular evidence of illness progression. Int. J. Neuropsychopharmacol. 17 1453–1463. 10.1017/S1461145714000443 [DOI] [PubMed] [Google Scholar]
  197. Phillips M. J., Voeltz G. K. (2016). Structure and function of ER membrane contact sites with other organelles. Nat. Rev. Mol. Cell Biol. 17 69–82. 10.1038/nrm.2015.8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Pick J. E., Ziff E. B. (2018). Regulation of AMPA receptor trafficking and exit from the endoplasmic reticulum. Mol. Cell. Neurosci. 91 3–9. 10.1016/j.mcn.2018.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Pilquil C., Alvandi Z., Opas M. (2020). Calreticulin regulates a switch between osteoblast and chondrocyte lineages derived from murine embryonic stem cells. J. Biol. Chem. 295 6861–6875. 10.1074/jbc.RA119.011029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Pobre K., Poet G. J., Hendershot L. M. (2019). The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: Getting by with a little help from ERdj friends. J. Biol. Chem. 294 2098–2108. 10.1074/jbc.REV118.002804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Polanczyk G. V., Willcutt E. G., Salum G. A., Kieling C., Rohde L. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. Int. J. Epidemiol. 43 434–442. 10.1093/ije/dyt261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Polanczyk G., de Lima M. S., Horta B. L., Biederman J., Rohde L. A. (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry 164 942–948. 10.1176/ajp.2007.164.6.942 [DOI] [PubMed] [Google Scholar]
  203. Prigge C. L., Kay J. N. (2018). Dendrite morphogenesis from birth to adulthood. Curr. Opin. Neurobiol. 53 139–145. 10.1016/j.conb.2018.07.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  204. Rapoport T. A. (2007). Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 450 663–669. 10.1038/nature06384 [DOI] [PubMed] [Google Scholar]
  205. Rauch F., Prud’homme J., Arabian A., Dedhar S., St-Arnaud R. (2000). Heart, brain, and body wall defects in mice lacking calreticulin. Exp. Cell Res. 256 105–111. 10.1006/excr.2000.4818 [DOI] [PubMed] [Google Scholar]
  206. Reyes S. T., Deacon R., Guo S. G., Altimiras F. J., Castillo J. B., van der Wildt B., et al. (2021). Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: Neurobehavioral phenotypes and receptor occupancy. Sci. Rep. 11:17150. 10.1038/s41598-021-94079-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  207. Riquelme P. A., Drapeau E., Doetsch F. (2008). Brain micro-ecologies: Neural stem cell niches in the adult mammalian brain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 123–137. 10.1098/rstb.2006.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  208. Rizzuto R., Duchen M. R., Pozzan T. (2004). Flirting in little space: The ER/mitochondria Ca2+ liaison. Sci. STKE 2004:re1. 10.1126/stke.2152004re1 [DOI] [PubMed] [Google Scholar]
  209. Robson M. J., Turner R. C., Naser Z. J., McCurdy C. R., O’Callaghan J. P., Huber J. D., et al. (2014). SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Exp. Neurol. 254 180–189. 10.1016/j.expneurol.2014.01.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  210. Roderick H. L., Lechleiter J. D., Camacho P. (2000). Cytosolic phosphorylation of calnexin controls intracellular Ca(2+) oscillations via an interaction with SERCA2b. J. Cell Biol. 149 1235–1248. 10.1083/jcb.149.6.1235 [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Roos A., Buchkremer S., Kollipara L., Labisch T., Gatz C., Zitzelsberger M., et al. (2014). Myopathy in Marinesco-Sjögren syndrome links endoplasmic reticulum chaperone dysfunction to nuclear envelope pathology. Acta Neuropathol. 127 761–777. 10.1007/s00401-013-1224-4 [DOI] [PubMed] [Google Scholar]
  212. Ropers H. H. (2010). Genetics of early onset cognitive impairment. Annu. Rev. Genomics Hum. Genet. 11 161–187. 10.1146/annurev-genom-082509-141640 [DOI] [PubMed] [Google Scholar]
  213. Rossi S., De Chiara V., Musella A., Cozzolino M., Bernardi G., Maccarrone M., et al. (2010). Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph. Lateral 11 83–90. 10.3109/17482960902977954 [DOI] [PubMed] [Google Scholar]
  214. Rosso I. M., Killgore W. D., Cintron C. M., Gruber S. A., Tohen M., Yurgelun-Todd D. A. (2007). Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol. Psychiatry 61 743–749. 10.1016/j.biopsych.2006.07.035 [DOI] [PubMed] [Google Scholar]
  215. Rubio M. E., Wenthold R. J. (1999). Calnexin and the immunoglobulin binding protein (BiP) coimmunoprecipitate with AMPA receptors. J. Neurochem. 73 942–948. 10.1046/j.1471-4159.1999.0730942.x [DOI] [PubMed] [Google Scholar]
  216. Ruegsegger C., Saxena S. (2016). Proteostasis impairment in ALS. Brain Res. 1648(Pt B) 571–579. 10.1016/j.brainres.2016.03.032 [DOI] [PubMed] [Google Scholar]
  217. Ruscher K., Inácio A. R., Valind K., Rowshan Ravan A., Kuric E., Wieloch T. (2012). Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. PLoS One 7:e45118. 10.1371/journal.pone.0045118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  218. Ruscher K., Shamloo M., Rickhag M., Ladunga I., Soriano L., Gisselsson L., et al. (2011). The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 134(Pt 3) 732–746. 10.1093/brain/awq367 [DOI] [PubMed] [Google Scholar]
  219. Rutter M., Kim-Cohen J., Maughan B. (2006). Continuities and discontinuities in psychopathology between childhood and adult life. J. Child Psychol. Psychiatry 47 276–295. 10.1111/j.1469-7610.2006.01614.x [DOI] [PubMed] [Google Scholar]
  220. Ryskamp D. A., Korban S., Zhemkov V., Kraskovskaya N., Bezprozvanny I. (2019). Neuronal sigma-1 receptors: Signaling functions and protective roles in neurodegenerative diseases. Front. Neurosci. 13:862. 10.3389/fnins.2019.00862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Sacco R., Gabriele S., Persico A. M. (2015). Head circumference and brain size in autism spectrum disorder: A systematic review and meta-analysis. Psychiatry Res. 234 239–251. 10.1016/j.pscychresns.2015.08.016 [DOI] [PubMed] [Google Scholar]
  222. Salinas P. C., Zou Y. (2008). Wnt signaling in neural circuit assembly. Annu. Rev. Neurosci. 31 339–358. 10.1146/annurev.neuro.31.060407.125649 [DOI] [PubMed] [Google Scholar]
  223. Samaco R. C., McGraw C. M., Ward C. S., Sun Y., Neul J. L., Zoghbi H. Y. (2013). Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum. Mol. Genet. 22 96–109. 10.1093/hmg/dds406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  224. Schmidt H. R., Kruse A. C. (2019). The molecular function of σ receptors: Past, present, and future. Trends Pharmacol. Sci. 40 636–654. 10.1016/j.tips.2019.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  225. Schwarz D. S., Blower M. D. (2016). The endoplasmic reticulum: Structure, function and response to cellular signaling. Cell. Mol. Life Sci. 73 79–94. 10.1007/s00018-015-2052-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Shepherd J. D., Bear M. F. (2011). New views of Arc, a master regulator of synaptic plasticity. Nat. Neurosci. 14 279–284. 10.1038/nn.2708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  227. Shih Y. Y., Nakagawara A., Lee H., Juan H. F., Jeng Y. M., Lin D. T., et al. (2012). Calreticulin mediates nerve growth factor-induced neuronal differentiation. J. Mol. Neurosci. 47 571–581. 10.1007/s12031-011-9683-3 [DOI] [PubMed] [Google Scholar]
  228. Shioda N., Beppu H., Fukuda T., Li E., Kitajima I., Fukunaga K. (2011). Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J. Neurosci. 31 346–358. 10.1523/JNEUROSCI.4816-10.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  229. Siegert R., Leroux M. R., Scheufler C., Hartl F. U., Moarefi I. (2000). Structure of the molecular chaperone prefoldin: Unique interaction of multiple coiled coil tentacles with unfolded proteins. Cell 103 621–632. 10.1016/s0092-8674(00)00165-3 [DOI] [PubMed] [Google Scholar]
  230. Smith S. M., Renden R., von Gersdorff H. (2008). Synaptic vesicle endocytosis: Fast and slow modes of membrane retrieval. Trends Neurosci. 31 559–568. 10.1016/j.tins.2008.08.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  231. So J., Warsh J. J., Li P. P. (2007). Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol. Psychiatry 62 141–147. 10.1016/j.biopsych.2006.10.014 [DOI] [PubMed] [Google Scholar]
  232. Sokolova E., Oerlemans A. M., Rommelse N. N., Groot P., Hartman C. A., Glennon J. C., et al. (2017). A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). J. Autism Dev. Disord. 47 1595–1604. 10.1007/s10803-017-3083-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  233. Solheim J. C., Harris M. R., Kindle C. S., Hansen T. H. (1997). Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. J. Immunol. 158 2236–2241. [PubMed] [Google Scholar]
  234. Stapleton M., Arunkumar N., Kubaski F., Mason R. W., Tadao O., Tomatsu S. (2018). Clinical presentation and diagnosis of mucopolysaccharidoses. Mol. Genet. Metab. 125 4–17. 10.1016/j.ymgme.2018.01.003 [DOI] [PubMed] [Google Scholar]
  235. Stranahan A. M., Erion J. R., Wosiski-Kuhn M. (2013). Reelin signaling in development, maintenance, and plasticity of neural networks. Ageing Res. Rev. 12 815–822. 10.1016/j.arr.2013.01.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  236. Su T. P., Hayashi T., Maurice T., Buch S., Ruoho A. E. (2010). The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 31 557–566. 10.1016/j.tips.2010.08.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Su T. P., Su T. C., Nakamura Y., Tsai S. Y. (2016). The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol. Sci. 37 262–278. 10.1016/j.tips.2016.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  238. Sudhof T. C. (2004). The synaptic vesicle cycle. Annu. Rev. Neurosci. 27 509–547. 10.1146/annurev.neuro.26.041002.131412 [DOI] [PubMed] [Google Scholar]
  239. Szabadkai G., Bianchi K., Várnai P., De Stefani D., Wieckowski M. R., Cavagna D., et al. (2006). Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J. Cell Biol. 175 901–911. 10.1083/jcb.200608073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  240. Tabata H., Nakajima K. (2001). Efficient in utero gene transfer system to the developing mouse brain using electroporation: Visualization of neuronal migration in the developing cortex. Neuroscience 103 865–872. 10.1016/s0306-4522(01)00016-1 [DOI] [PubMed] [Google Scholar]
  241. Tahmaz I., Shahmoradi Ghahe S., Topf U. (2022). Prefoldin function in cellular protein homeostasis and human diseases. Front. Cell Dev. Biol. 9:816214. 10.3389/fcell.2021.816214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  242. Takeuchi T. (2018). Non-cell autonomous maintenance of proteostasis by molecular chaperones and its molecular mechanism. Biol. Pharm. Bull. 41 843–849. 10.1248/bpb.b18-00141 [DOI] [PubMed] [Google Scholar]
  243. Tan Q., Zoghbi H. Y. (2019). Mouse models as a tool for discovering new neurological diseases. Neurobiol. Learn. Mem. 165:106902. 10.1016/j.nlm.2018.07.006 [DOI] [PubMed] [Google Scholar]
  244. Tashiro E., Zako T., Muto H., Itoo Y., Sörgjerd K., Terada N., et al. (2013). Prefoldin protects neuronal cells from polyglutamine toxicity by preventing aggregation formation. J. Biol. Chem. 288 19958–19972. 10.1074/jbc.M113.477984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  245. Thapar A., Cooper M., Rutter M. (2017). Neurodevelopmental disorders. Lancet Psychiatry 4 339–346. 10.1016/S2215-0366(16)30376-5 [DOI] [PubMed] [Google Scholar]
  246. Tjoelker L. W., Seyfried C. E., Eddy R. L., Jr., Byers M. G., Shows T. B., Calderon J., et al. (1994). Human, mouse, and rat calnexin cDNA cloning: Identification of potential calcium binding motifs and gene localization to human chromosome 5. Biochemistry 33 3229–3236. 10.1021/bi00177a013 [DOI] [PubMed] [Google Scholar]
  247. Torpe N., Gopal S., Baltaci O., Rella L., Handley A., Korswagen H. C., et al. (2019). A protein disulfide isomerase controls neuronal migration through regulation of Wnt secretion. Cell Rep. 26 3183–3190.e5. 10.1016/j.celrep.2019.02.072 [DOI] [PubMed] [Google Scholar]
  248. Tripp G., Wickens J. R. (2009). Neurobiology of ADHD. Neuropharmacology 57 579–589. 10.1016/j.neuropharm.2009.07.026 [DOI] [PubMed] [Google Scholar]
  249. Trujillo C. M., Alonso A., Delgado A. C., Damas C. (2005). The rostral and caudal boundaries of the diencephalon. Brain Res. Brain Res. Rev. 49 202–210. 10.1016/j.brainresrev.2005.01.002 [DOI] [PubMed] [Google Scholar]
  250. Tsai S. Y., Hayashi T., Harvey B. K., Wang Y., Wu W. W., Shen R. F., et al. (2009). Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc. Natl. Acad. Sci. U.S.A. 106 22468–22473. 10.1073/pnas.0909089106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  251. Tsuboyama K., Tadakuma H., Tomari Y. (2018). Conformational activation of argonaute by distinct yet coordinated actions of the Hsp70 and Hsp90 chaperone systems. Mol. Cell 70 722–729.e4. 10.1016/j.molcel.2018.04.010 [DOI] [PubMed] [Google Scholar]
  252. Turano C., Coppari S., Altieri F., Ferraro A. (2002). Proteins of the PDI family: Unpredicted non-ER locations and functions. J. Cell. Physiol. 193 154–163. 10.1002/jcp.10172 [DOI] [PubMed] [Google Scholar]
  253. Turrero García M., Harwell C. C. (2017). Radial glia in the ventral telencephalon. FEBS Lett. 591 3942–3959. 10.1002/1873-3468.12829 [DOI] [PMC free article] [PubMed] [Google Scholar]
  254. Turrigiano G. G. (2008). The self-tuning neuron: Synaptic scaling of excitatory synapses. Cell 135 422–435. 10.1016/j.cell.2008.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  255. Tyson J. R., Stirling C. J. (2000). LHS1 and SIL1 provide a lumenal function that is essential for protein translocation into the endoplasmic reticulum. EMBO J. 19 6440–6452. 10.1093/emboj/19.23.6440 [DOI] [PMC free article] [PubMed] [Google Scholar]
  256. van Schadewijk A., van’t Wout E. F., Stolk J., Hiemstra P. S. (2012). A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17 275–279. 10.1007/s12192-011-0306-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  257. Villard V., Espallergues J., Keller E., Vamvakides A., Maurice T. (2011). Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J. Psychopharmacol. 25 1101–1117. 10.1177/0269881110379286 [DOI] [PubMed] [Google Scholar]
  258. Vuppalanchi D., Coleman J., Yoo S., Merianda T. T., Yadhati A. G., Hossain J., et al. (2010). Conserved 3’-untranslated region sequences direct subcellular localization of chaperone protein mRNAs in neurons. J. Biol. Chem. 285 18025–18038. 10.1074/jbc.M109.061333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  259. Wang J., Lee J., Liem D., Ping P. (2017). HSPA5 gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. Gene 618 14–23. 10.1016/j.gene.2017.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  260. Wang M., Wey S., Zhang Y., Ye R., Lee A. S. (2009). Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid. Redox Signal. 11 2307–2316. 10.1089/ars.2009.2485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  261. Wang T., Liu K., Li Z., Xu Y., Liu Y., Shi W., et al. (2017). Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China: A systematic review and meta-analysis. BMC Psychiatry 17:32. 10.1186/s12888-016-1187-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  262. Wang Z. H., Chen Y. X., Zhang C. M., Wu L., Yu Z., Cai X. L., et al. (2011). Intermittent hypobaric hypoxia improves postischemic recovery of myocardial contractile function via redox signaling during early reperfusion. Am. J. Physiol. Heart Circ. Physiol. 301 H1695–H1705. 10.1152/ajpheart.00276.2011 [DOI] [PubMed] [Google Scholar]
  263. Wang Z., Hong Y., Zou L., Zhong R., Zhu B., Shen N., et al. (2014). Reelin gene variants and risk of autism spectrum disorders: An integrated meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 165B 192–200. 10.1002/ajmg.b.32222 [DOI] [PubMed] [Google Scholar]
  264. Weiss L. A., Shen Y., Korn J. M., Arking D. E., Miller D. T., Fossdal R., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. N. Engl. J. Med. 358 667–675. 10.1056/NEJMoa075974 [DOI] [PubMed] [Google Scholar]
  265. Whangbo J., Kenyon C. (1999). A Wnt signaling system that specifies two patterns of cell migration in C. elegans. Mol. Cell 4 851–858. 10.1016/s1097-2765(00)80394-9 [DOI] [PubMed] [Google Scholar]
  266. Wilkinson B., Gilbert H. F. (2004). Protein disulfide isomerase. Biochim. Biophys. Acta 1699 35–44. 10.1016/j.bbapap.2004.02.017 [DOI] [PubMed] [Google Scholar]
  267. Willert K., Nusse R. (2012). Wnt proteins. Cold Spring Harb. Perspect. Biol. 4:a007864. 10.1101/cshperspect.a007864 [DOI] [PMC free article] [PubMed] [Google Scholar]
  268. Willis D., Li K. W., Zheng J. Q., Chang J. H., Smit A. B., Kelly T., et al. (2005). Differential transport and local translation of cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J. Neurosci. 25 778–791. 10.1523/JNEUROSCI.4235-04.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  269. Wilson P. J., Morris C. P., Anson D. S., Occhiodoro T., Bielicki J., Clements P. R., et al. (1990). Hunter syndrome: Isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc. Natl. Acad. Sci. U.S.A. 87 8531–8535. 10.1073/pnas.87.21.8531 [DOI] [PMC free article] [PubMed] [Google Scholar]
  270. Wraith J. E., Rogers J. G., Danks D. M. (1987). The mucopolysaccharidoses. Aust. Paediatr. J. 23 329–334. 10.1111/j.1440-1754.1987.tb00284.x [DOI] [PubMed] [Google Scholar]
  271. Xavier J. M., Rodrigues C. M., Solá S. (2016). Mitochondria: Major regulators of neural development. Neuroscientist 22 346–358. 10.1177/1073858415585472 [DOI] [PubMed] [Google Scholar]
  272. Yamaguchi K., Shioda N., Yabuki Y., Zhang C., Han F., Fukunaga K. (2018). SA4503, a potent sigma-1 receptor ligand, ameliorates synaptic abnormalities and cognitive dysfunction in a mouse model of ATR-X syndrome. Int. J. Mol. Sci. 19:2811. 10.3390/ijms19092811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  273. Yan M., Li J., Sha B. (2011). Structural analysis of the sil1-bip complex reveals the mechanism for sil1 to function as a nucleotide-exchange factor. Biochem. J. 438 447–455. 10.1042/BJ20110500 [DOI] [PubMed] [Google Scholar]
  274. Yashiro K., Philpot B. D. (2008). Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 55 1081–1094. 10.1016/j.neuropharm.2008.07.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  275. Yoshikawa S., McKinnon R. D., Kokel M., Thomas J. B. (2003). Wnt-mediated axon guidance via the Drosophila derailed receptor. Nature 422 583–588. 10.1038/nature01522 [DOI] [PubMed] [Google Scholar]
  276. Zablotsky B., Black L. I., Maenner M. J., Schieve L. A., Blumberg S. J. (2015). Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 national health interview survey. Natl. Health Stat. Rep. 87 1–20. [PubMed] [Google Scholar]
  277. Zarrei M., Burton C. L., Engchuan W., Young E. J., Higginbotham E. J., MacDonald J. R., et al. (2019). A large data resource of genomic copy number variation across neurodevelopmental disorders. NPJ Genom. Med. 4:26. 10.1038/s41525-019-0098-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  278. Zeeshan H. M., Lee G. H., Kim H. R., Chae H. J. (2016). Endoplasmic reticulum stress and associated ROS. Int. J. Mol. Sci. 17:327. 10.3390/ijms17030327 [DOI] [PMC free article] [PubMed] [Google Scholar]
  279. Zhang X., Abreu J. G., Yokota C., MacDonald B. T., Singh S., Coburn K. L., et al. (2012). Tiki1 is required for head formation via Wnt cleavage-oxidation and inactivation. Cell 149 1565–1577. 10.1016/j.cell.2012.04.039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  280. Zhang C. L., Feng Z. J., Liu Y., Ji X. H., Peng J. Y., Zhang X. H., et al. (2012). Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: A novel mechanism for methylphenidate action. PLoS One 7:e51910. 10.1371/journal.pone.0051910 [DOI] [PMC free article] [PubMed] [Google Scholar]
  281. Zhang K., Kaufman R. J. (2008). From endoplasmic-reticulum stress to the inflammatory response. Nature 454 455–462. 10.1038/nature07203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  282. Zhang X. M., Yan X. Y., Zhang B., Yang Q., Ye M., Cao W., et al. (2015). Activity-induced synaptic delivery of the GluN2A-containing NMDA receptor is dependent on endoplasmic reticulum chaperone bip and involved in fear memory. Cell Res. 25 818–836. 10.1038/cr.2015.75 [DOI] [PMC free article] [PubMed] [Google Scholar]
  283. Zhao P., Ignacio S., Beattie E. C., Abood M. E. (2008). Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: Implications for excitotoxicity. Eur. J. Neurosci. 27 572–579. 10.1111/j.1460-9568.2008.06041.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  284. Zhemkov V., Geva M., Hayden M. R., Bezprozvanny I. (2021). Sigma-1 receptor (S1R) interaction with cholesterol: Mechanisms of S1R activation and its role in neurodegenerative diseases. Int. J. Mol. Sci. 22:4082. 10.3390/ijms22084082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  285. Zheng P. (2009). Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. Prog. Neurobiol. 89 134–152. 10.1016/j.pneurobio.2009.07.001 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES